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ABSTRACT

Nonprofit organizations vary in size and capacity. They often start with a
small group of passionate people brought together with a common focus. Often
their mission has a direct impact on the individual member or their communities
and loved ones. Today there are over 7,000 identified rare diseases and rare
disease advocacy organizations representing patients and families that singularly
are small in numbers. In the aggregate, however they represent one-in-ten
individuals worldwide. This paper presents a case study of one rare disease
advocacy organization from the perspective of an organizational consultant who
is also a parent and advocate in the rare disease community. Building upon the
case study, the paper includes a review of existing research and literature and
interviews with other leaders in the nonprofit and rare disease advocacy
community. The capstone examines leadership and other components of
nonprofit organizations, including the role of the consultant, that help bring about
transformative change and innovation within this sector.
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CHAPTER 1
INTRODUCTION
Nonprofit organizations vary in size and capacity. They often start with a
small group of passionate people brought together with a common goal. As of
2012, there were over 1.5 million registered nonprofit organizations in the United
States (Roeger, p.5). Approximately three quarters of these organizations had
operating budgets of less than $500,000 per year, many of them much smaller
(2012, p.149). Many small nonprofit organizations, often characterized as
“grassroots,” share a similar profile in that they are led by members with a high
level of passion and energy towards a singular mission. Often times the mission
has a direct impact on the individual or their communities and loved ones.
Rare disease organizations are especially challenged as their small
numbers draw on much more finite resources and the gravity and urgency of
their mission have life and death implications. In many cases they are
represented by “kitchen-table” groups formed by parents of patients or even
patients themselves and represent those impacted diseases that have been
diagnosed less than 200,000 times (Dunkle, 2014, p.19). Over 7,000 rare
diseases have been identified, some with patient populations in single digits and
many with less than one thousand identified patients. Collectively, they
represent more than 300 million people across the world. 50% of those
diagnosed are children (Global Genes Alliance, 2015). These organizations
demonstrate extreme passion and resiliency. To be truly effective, they must
collaborate with other umbrella organizations such as the National Organization
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for Rare Diseases (NORD), Global Genes, their governments, and universities
such as the University of Pennsylvania’s Orphan Disease Center, research
centers, pharmaceutical companies, and each other. Despite these extreme
challenges, many have grown to become model organizations that meet the
increasing heavy load of their patient communities. As research and drug
therapies have advanced, so have the needs of their constituents.
There has been little written with a specific focus on rare disease
advocacy organizations. Similar to other nonprofit organizations, their focus on
mission and outcomes rather than financial returns call for unique attributes in
their leadership, members and operations. This capstone offers a case study of a
recent consulting engagement that took place with a rare disease organization.
In addition to the case study, the capstone asks what separates the
nonprofit sector from for-profit enterprises and explores the unique challenges
and perspectives in the rare disease community. It also explores the role of the
consultant and organizational development practitioner when working with
nonprofit organizations and includes a survey with leaders of other small
nonprofit organizations, including past and present Board members, Board
Presidents and Executive Directors of several rare disease and grass-root
organizations who discuss the trajectory of their organizations and how they may
have been positively or negatively impacted when working with consultants.
These are presented over the next four chapters that are described below.
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The DCO Case Study
The case study recounts a recent consulting engagement with a small rare
disease advocacy group. It includes my own history as a parent and advocate for
a child with Dyskeratosis Congenita (DC), a rare biological telomere disorder. It
shares the story of the consulting engagement with DC Outreach, Inc. (DCO) that
I completed with classmate Bob Biglin and our advisor, Dr. Charline Russo as
part of the University of Pennsylvania’s Master’s of Science in Organizational
Dynamics - Organizational Consulting and Executive Coaching cohort program.
The objective of this engagement was to help DCO’s leaders develop a strategic
plan that was grounded on the past successes of the organization and leverage
their strengths to help them identify a common vision that would build their
organizational capacity and effectively lead their growing patient and caregiver
community into the future.
DCO was formed in 2006 by a small group of patients and parents with
the following mission:
Our Mission is to provide information and support services to families
worldwide affected by Dyskeratosis Congenita and Telomere Biology
Disorders to encourage the medical community’s research in finding
causes and effective treatments, and to facilitate improved diagnosis
by educating medical providers. (Dyskeratosis Congenita Outreach,
Inc.).
This engagement had special meaning, as my oldest son Josh was lost to
DC five years ago after battling this disease for over seventeen years. When
Josh was diagnosed with DC in 2002, he was one of less than 400 individuals in
the world to ever have been diagnosed with this disease. Since Josh’s
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diagnoses, DC has been diagnosed in over 1,000 additional individuals.
Although DC is considered an extremely rare “orphan disease,” it is believed that
it goes undiagnosed more often than not. The DC and biological telomere
disorder (BTD) community believe that diagnoses will continue to grow as
doctors become more educated and aware in identifying these underlying
conditions as they encounter them when treating their symptoms (Olson, 2016).
We found DCO to be an organization that has punched well above its weight as
their past accomplishments have moved mountains, yet they are faced with
much more to do with limited and tired resources.
The Literature Review
Building from the experiences of the DCO case study, the literature review
includes a blend of peer-reviewed articles, books and on-line sources that
explore prevalent factors towards building the organizational capacity and
effectiveness of non-profit organizations. Building from the experiences and
learning of the DCO case study, the literature review focuses these observations
to the following areas:
•

Rare disease advocacy organizations – a brief retrospect on the
emergence of rare disease patient advocacy organizations and what
factors separate these organizations from other nonprofits. The history
of the National Organization for Rare Disorders, a leading advocacy
group representing thousands of rare disease organizations since the
passing of the Orphan Drug Act in 1983 is presented to help frame the
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unique challenges encountered by rare disease advocacy
organizations.
•

The nonprofit/consultant relationship – An examination of what
methodologies and applications are most effective when working with
nonprofit organizations as a consultant and how these relationships
have helped lead these organizations to grow in effectiveness,
innovation and capacity. Penolope Cagney’s book Nonprofit
Consulting Essentials provides insight in regard to the consultant’s
journey with nonprofits, and an analysis of the appreciative inquiry
utilized with the DCO engagement is further examined.

•

Leadership and innovation in nonprofit organizations – qualities and
challenges that distinguish the nonprofit sector from for-profit
enterprises. This section includes articles, research and insights from
Peter Drucker and Frances Hesselbein that help set the foundation of
the unique attributes found in the nonprofit sector. It also examines
research in regard to approaches in building organizational capacity
and innovation with such organizations as the Association of Retarded
Citizens (ARC) and studies with leaders from other small nonprofit
organizations.

Research Methodology, Assumptions, Data and Analysis
In addition to my own experiences with DCO, Chapter four includes
insights from leaders of other nonprofit organizations, including those from the
rare disease community. Those included in the interview process were some of
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the most innovative and passionate people I’ve ever met. Each of the interviews
offered fascinating perspectives of the inspirational journeys that each of the
represented grass-root organizations encountered as they continue to grow and
help others cope, advance research and overcome obstacles that are encounter
at the most personal level.
Summary & Conclusions
Chapter five provides a summation of observations and findings
discovered in the case study, the literature review and the survey of other
nonprofit leaders. The chapter presents questions and research opportunities to
consider that were not within the scope of this study, but would be valuable to
pursue. The chapter concludes with my own reflections and thoughts in regard
to the capstone experience and how this experience has influenced me as a
parent, advocate, coach and consultant now and in the future.
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CHAPTER 2
THE DCO CASE STUDY
The summer of 2016 was a rewarding time as my Penn OCEC Cohort V
classmate Bob Biglin and I partnered under the supervision and guidance of Dr.
Charline Russo to help an organization that has worked with few resources and a
large mission. Dyskeratosis Congenita Outreach, Inc. is a 501c(3) advocacy and
support group that serves patients and caregivers of Dyskeratosis Congenita
(DC), a rare disease diagnosed in less than one in every one million people in
the world. A recent article in Penn Today described DC as follows:
DC, is a rare, inherited disease for which there are limited treatment
options and no cure. Typically diagnosed in childhood, the disorder
causes stem cells to fail, leading to significant problems including bone
marrow failure, lung fibrosis, dyskeratosis of the skin and intestinal atrophy
and inflammation. Patients are also at heightened risk of several types of
cancer. A common underlying feature of the disease is the presence of
shortened telomeres. Telomeres are the structures that protect, or “cap,”
the ends of chromosomes, but they tend to shorten with cell division and
age, and can thus lose their protective functions. Many DC patients have a
mutation in the DKC1 gene, which codes for a component of the enzyme
called telomerase that helps maintain telomere length. Because
telomerase is most essential in tissues that divide frequently, notably,
epithelial tissues such as the skin, gut and lungs, this is where defects
crop up in these individuals. (Baillie, 2016).
This engagement had special meaning, as my oldest son Josh was lost to
DC five years ago after battling this disease for over seventeen years. When
Josh was diagnosed with DC in 2002, there were less than 400 others ever
diagnosed with this rare telomere disorder. Since then, DC has been diagnosed
in over 1,000 other individuals. The DC and biological telomere disorder
community believe that diagnoses will continue to grow as doctors become more
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educated and aware in identifying DC manifestations in other conditions as they
encounter them when treating their symptoms (Olson, 2016).
In 2006 a small group of patients and caregivers affected by DC formed
DC Outreach, Inc. with the following mission:
Our Mission is to provide information and support services to families
worldwide affected by Dyskeratosis Congenita and Telomere Biology
Disorders to encourage the medical community’s research in finding
causes and effective treatments, and to facilitate improved diagnosis
by educating medical providers. (https://www.dcoutreach.org).

My relationship with DC & DCO
I am a parent of a child lost to DC. Today those words are difficult to say
and accept. They sadden and anger me. They are part of my identity and serve
to inspire how I choose to move forward.
Through the first fifteen years of Josh’s life, my wife Pattie and I had
never met anyone, with the exception of doctors, who had any affiliation with this
extremely rare condition. Josh was our first-born. As new parents, we felt
confused and alone as we began understanding his condition and realizing his
severe feeding issues, lack of growth, microcephaly and cognitive delays, and his
phantom fevers in the middle of the night we were experiencing were not normal
or healthy. It took eight years before a definitive diagnoses was reached. DC is
so rare, and there are so few data points, we found ourselves at the forefront of
the unknown. We resisted looking too far into the future and committed
ourselves to living our lives with Josh in the moment. We rarely thought of Josh
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as sick or disabled. To us he has always been and still is an integral part of our
family.
Josh’s first three years of life included severe feeding issues, a failure to
gain weight and grow, and an understanding that he would need help throughout
his life. At the age of three Josh weighed only seven-teen pounds, had difficulty
walking and talking and was constantly tired and sick. At this time, we spent
four months at the Seashore House at the Children’s Hospital of Philadelphia
(CHOP). After surviving some significant medical scares and setbacks, we were
still without a diagnosis. We brought Josh home the week before the Christmas
of 1997. He was stronger, walking and talking, and we could see that he would
have a chance to live a viable and impactful life. We still did not have a
diagnosis; however, we knew his immune system was compromised and began
a life of treatments and doctor visits between school and activities.
When Josh was eight, Dr. Katherine Sullivan (“Dr. Kate” as we came to
know her), an immunologist at CHOP, began to narrow down what she thought
may be Josh’s underlying condition. Dr. Sullivan along with the top geneticists at
CHOP tested for multiple immunological disorders, syndromes and rare
conditions. Ultimately, through collaboration with Dr. Indergeet Dokal, a DC
specialist from Hammersmith Hospital in England, we were able to pinpoint
Dyskeratosis Congenita as Josh’s underlying diagnosis.
When we learned of Josh’s diagnosis, we traveled to Hammersmith and
met Dr. Dokal. He was a resource to us through Josh’s life and remains a friend
to the DC community and our family. Having a diagnosis did not bring much
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relief nor did it lessen the fear we were experiencing as a family. We were still
alone and Josh was only the 365th DC patient identified with DC that Dr. Dokal
was aware of as he maintained a registry of DC patients from around the world.
There were no support groups, massively attended walks or bike rides,
broadcasts telethons, or Ice Bucket Challenges to spread awareness, raise
money or provide connectivity for the few hundred people in the world diagnosed
with this rare and little understood disease.
What we did find was local support from our friends, family and the special
needs community in Voorhees, New Jersey and later in West Chester,
Pennsylvania, where we now live. For fifteen years we managed Josh’s care
along with raising our younger children Noah and Katie. We were all affected as
DC was part of our “normal” lives. At this time, Josh’s care was manageable and
with the exception of a few setbacks, his health was relatively stable. Our focus
was more on family, friends and wellness rather than the science or advocacy
that comes with a rare disease. This all changed during the winter of 2010.
One of the main complications for patients with DC is bone marrow failure.
Josh’s bone marrow was tested and monitored each year and for the first fifteen
years of his life, it remained relatively healthy and stable. In early 2010 his
annual bone marrow test revealed a decline in red-cell production and we began
to see the first cracks in what had once been a manageable disease.
In addition to being a member of his drama club and a year-round
participant and camper at Bournelyf Special Camp, Josh also played Challenger
League baseball. The Challenger League included teams with children and

11

young adults with various physical and cognitive challenges along with “buddies”
that helped them learn and perform the fundamentals of baseball. As a parent,
the league offered a great social connection with the special needs community.
It also offered weekly games that were incredibly slow to watch. One of the
Challenger League rules is that each player has an at-bat in each inning.
Thankfully the games were only three innings. The last player each inning would
clear the bases with a home run. Every game ended in a tie. During a game
early in the 2010 season, Josh was the cleanup hitter. When he hit his home
run he struggled to get around the bases. When we hugged in the dugout I could
see he was exhausted and he asked if I could pull him out of the game. I knew
that we were heading towards a bad place.

A few weeks later Josh had another appointment with his hematologist
who was quickly learning about DC. He had never heard of, none-the-less
treated anyone, with this rare condition before Josh. After several more tests, we
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were told that Josh’s condition would only get worse and that the remainder of
his life would be measured in months, not years.
As a parent of a child with a chronic illness, I would often find myself up
late at night searching online for new information about DC. Shortly after
realizing that things were not going to get better for Josh, I found a web-site
called DC Outreach, a small support group for those dealing with DC. By now, it
had been eight years since we had a name for Josh’s disease. I quickly saw that
there was a patient community, albeit small, for others coping with this disease.
DCO’s logo was “You are not alone”. I briefly shared Josh’s story on the site and
within a day I heard back from DCO’s President, Nancy Cornelius. I learned that
Nancy lived with her family in New York. Nancy was diagnosed with DC while in
her forties and she had a son, Charlie who was also diagnosed with DC. At this
time Charlie was a student and member of the diving team at Villanova
University. I also learned of another family who lived in New York, and whose
father Seth, was originally from Lower Merion, Pennsylvania, and had a oneyear-old daughter just diagnosed with DC. The next day I spoke with Seth and
we realized that we grew up within a few miles from each other and albeit 10years apart, we went to the same high school (Seth was at Lower Merion during
the Kobe Bryant years, about ten years after I graduated). A few weeks later,
Josh and I had lunch at Villanova with Charlie. Suddenly we weren’t feeling so
alone.
We had found a community and soon expanded our network to doctors
and others who were some of the few in the world that understood this disease.
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Through DCO, we also learned that we did not need to go back to London for
care. Dr. Monica Bessler, a colleague of Dr. Dokal’s at Hammersmith Hospital
had recently come to practice and chair the Hematology department at CHOP.
Dr. Bessler along with her Resident colleague Dr. Tim Olsen, who succeed Dr.
Bessler after her retirement and was a contributor to the DCO engagement as
well as this study, were the very best people we could have met to support us
through the final chapter of Josh’s life. They were both extremely
knowledgeable, caring and compassionate. They were with us through Josh’s
final months and days until his last breath. Sadly, Josh’s health continued to
deteriorate. We knew with Dr. Bessler, Dr. Olson and Dr. Sullivan at CHOP we
had access to the best possible care in the world for Josh. At the age of
seventeen, on November 18, 2011, Josh passed away. DCO had become a
lifeline for us as we confronted this disease, grieved our loss and gained the
support and knowledge offered from this tight-knit community.
Three years after losing Josh, I began working at the University of
Pennsylvania. Part of what drew me to Penn was continuing the Organizational
Dynamics (OD) program. I had started in 2001, but stopped after taking three
courses as Josh’s medical needs took precedent. Working at Penn offered me
the unique experience to become closer with the doctors and researchers that I
had gotten to know over the years that helped Josh. It also provided an
opportunity to reengage in the OD program. I rejoined the program with a
greater focus than I had when I started it. I wanted to help others who were
dealing with similar challenges that I had as a parent and professional managing
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an acute medical condition and facing the loss of a child. The Organizational
Consulting and Executive Coaching cohort program offered by the OD curriculum
was the ideal place to pursue this mission.
From parent and advocate to consultant
Two years after losing Josh and shortly after beginning my work at Penn, I
became a DCO board member. DCO’s monthly Board calls were always
awkward for me. The Board meets monthly on the second Sunday night at 9PM.
This time is difficult, but has worked best for its members as they are calling in
from each of the US time zones and sometimes from the other side of the world.
This was a large part of why I eventually left DCO’s board. Sunday night is
typically when my wife and I unwind together on our couch, so disrupting this to
relive our DC experience became a hindrance toward coping with the loss of
Josh. I also felt many of the topics that consumed these calls, often late into the
evening, were things that could be better resolved with other DCO members and
were not reliant on my input. The following e-mail to DCO’s Board President and
Treasurer was difficult to write, but expressed my thoughts at this time.
On Sat, Mar 12, 2016 at 3:01
User <bwf819@yahoo.com> wrote:

PM,

Microsoft

Office

Robin, Lisa - This morning I was on a training ride for the MDBR and
as often happens, I found myself lost in my thoughts. I want to share
with you as we’ve gotten to know each other a bit over the years. I
apologize for the long note, but you’ve both been helpful to me over
the last couple of years and I’d like to share this with you.
I admire both of you for your resilience and determination as you
fight through DC and endlessly work to help others as well as
yourselves. Your energy and perseverance are truly inspirational.
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I now find myself four + years since Josh passed away. My son Noah
is now older than Josh was when he passed and will be entering
Millersville University this fall. My daughter Katie is 15 and truly an
exceptional student, dancer and young lady. Pattie and I continue to
grieve but now find ourselves thinking more about Josh’s life and less
about what we went through managing a terminal disease. It’s been
a difficult road getting to where we are and I’m beginning to
understand more now that it’s time to focus more on what’s in front
of us and ahead of us while continuing to honor Josh’s memory.
Over the last ten months, I’ve been engaged in a degreed executive
coaching and Masters program at Penn. When I accepted a position
at the University, I took a large cut in pay, but was motivated to do
so as I’ve always felt a strong closeness to CHOP and Penn, I also
wanted to help other grieving parents or those with children with
chronic illnesses who have professional careers as I’ve experienced
all of that myself and I found Penn offered me an opportunity to
pursue that goal. Now that I’m about half way through the program,
I realize that I do enjoy coaching and I think I’ll be pretty good at it,
but I need to figure out how to transition this into a career and also
realize that it’s much broader than the initial goal that motivated me
to start.
I joined the DC Outreach Board last year following for a few
reasons. One was I had reached out to Dr. Bessler ad Dr. Olson
who had treated Josh and was with us as he took his last breath to
ask how I could help other DC families at Penn, she suggested I
become involved again with DC Outreach. I also was grateful for the
support DC Outreach and in particular Nancy Cornelius who were
with us as Josh’s health began to deteriorate and we began to
understand that his condition was not going to get better. Lastly, I felt
obligated as Josh’s Dad to honor his memory and help others.
The challenge I’ve had and continue to have is that I’m stretched
pretty thin. I started a new position within Penn this past January,
I’m also still active with the board for Josh’s camp, which is right down
the street from where we live and includes families that we’ve
become very close to throughout Josh’s life. It’s also helpful to us
that Pattie, Noah and Katie are all involved with the camp throughout
the year. Another challenge that has become more apparent is that
it’s becoming more emotionally draining for me to actively participate
in DC Outreach. I feel that I contribute a lot with my board
experiences and resources at Penn, but calling in on Sunday nights
and other nights is a disruptive and difficult reminder to me as well
as Pattie and our kids as we continue to move forward as a family. I
stopped calling into the family calls which are wonderful, after Josh
passed away, as it was too difficult to listen to others going through
what we had and I did not feel I could offer much hope, especially as
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difficult as the last 18 months of Josh’s life was. Whereas this was
once a way to help me cope with grieving, it’s become more of a
hindrance in moving through the grieving process. That’s in large
part why I’ve limited my participation to the monthly calls. I don’t feel
I’ve been as good a board member as I should be and right now, I
don’t think I can, it’s hard for me to say that, but it’s how I feel.
I’d like to remain a friend and resource to DC Outreach. I’m glad to
continue to help as an advisor or maintaining relationships with Penn,
but I don’t think it’s productive for me to continue on the Board.
I will call into tomorrow night’s meeting as I have a few items on the
agenda. I don’t want to make a big deal about this on the call, and I’d
like to get your thoughts on how and if I can best contribute without
being a full-fledged board member before doing anything “official”.
I appreciate your friendship and hope that you can understand how
difficult this decision is for me, but I think it’s one I need to make.
Best,
Bruce

After leaving the DCO Board, I wanted to maintain my connection with the
organization. The OCEC cohort has been a transformational experience for me
as I realized I would want to eventually transition my career from that of a finance
professional to a coach and consultant. As part of the Cohort program, we were
required to complete a consulting field experience. I could not think of a more
rewarding experience than working with DCO. At this time I approached my
classmate, Bob Biglin, with this idea and after we thought through an initial
approach, we presented this plan to our advisor, Dr. Charline Russo.
As a parent of a child lost to DC and who found help and support from
DCO during the most difficult time of our lives, and as a former board member of
DCO, I struggled with defining my role as a consultant. I had known the Board
members via phone and Internet, and even a few in-person contacts over the
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past seven years. When Bob and I introduced our proposal to the Board
members, I knew I needed to make the shift from DC parent and advocate to
consultant. I was concerned my emotions would get in the way, and would result
in the transference of my own experience with DC and rare diseases. I knew I
needed to be objective and open myself up to the truths and experiences of other
people. Getting out of one’s own way is not an uncommon area of development
for coaches and consultants, yet my concern was amplified as DC has had such
a profound impact on my life and my immediate and extended family.
Developing a new relationship with DCO’s Board
Over the past several years, DC has been diagnosed more frequently and
the patient pool continues to expand. Consequently, DCO’s Board finds itself
working with a small budget and often searching for expertise and resources that
are needed outside of the DC families that they serve. The Board consists of a
small group of DC patients and caregivers, many physically and financially
exhausted from the implications of managing a chronic illness. Until recently,
only those directly impacted by the disease were board members. The disease
has devastating implications to each patient’s health and the well being of the
patient and their caregivers. The current board members all shared a feeling of
“burn-out” and felt they had so much to do with very little energy to continue to
advocate and carry out their mission.
Through Board calls and other interactions with DCO’s Board,
transitioning my role as a board member to a consultant would be difficult for
DCO’s Board members and me. As Bob and I introduced the consulting
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engagement to the Board during their August monthly Board Call, there was
awkward silence. I realized about halfway through our meeting that we did not
do a very good job setting the table and jumped right into the content and
approach of the consulting engagement. This was in large part my own doing as
I initiated the discussion, but forgot to introduce Bob to the other board members.
This was the result of my own anxious energy and I realized we had lost our
audience. I stopped in the middle of our presentation and acknowledged that I
had not set up our discussion appropriately. We then took the time to introduce
ourselves and asked each member what their thoughts and concerns may be as
we outlined the proposal. This followed with a much more robust discussion and
we left the Board meeting with the promise they would get back to us in the next
several days with a decision in regard to proceeding with the engagement.
At this moment I realized, that although I knew I needed to manage myself
carefully through the engagement and avoid assumptions based on my own
experiences, I also needed to step back and breathe. I needed to be very
deliberate in my interactions with DCO and balance the experiences that I was
bringing to this engagement, with objectivity and professionalism. After the call,
Bob and I spoke. I shared my feelings with Bob and we both recognized even
more clearly how much we needed each other to effectively move forward with
DCO.
Although maintaining a professional distance during the engagement with
DCO presented a challenge to be managed, it was also an asset in truly
understanding and helping the organization. As described in Edgar Schein’s
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Humble Consulting, I had entered the DCO engagement already with a “Level
Two Relationship”, that is a more personal, more trusting and open relationship
with DCO board members than typically experienced from an outsider’s point of
view (2016, p. 15). Schein describes humble consulting as a consulting
relationship that presumes the consultant is committed to being helpful, bringing
a great deal of honest curiosity, and having a caring attitude. Even though I had
an extensive relationship with DCO in the past, working with them as a
consultant was new and it was important that Bob and I engaged in what Schein
describes as the “personalization process”. We needed to get to know DCO and
understand their true challenges by demonstrating genuine curiosity, caring and
a commitment to helping. This process proved valuable in establishing a
relationship-building process that would be used throughout the engagement and
would lead to interactions that the client would find immediately helpful (2016, p.
13). I needed to recalibrate and re-personalize my relationship with DCO.
Building this relationship and establishing an awareness of how my
relationship with DCO was influencing this new engagement was an important
step in helping DCO understand their capacity for change and growth. As our
work progressed, I was able to find a middle ground and balance what had
become a very personal and close relationship with some of DCO’s board
members over the years. The new context of our relationship enabled me to
avoid becoming what Schein refers to as “content-seduced” and better manage
myself to focus on the various processes that were occurring between DCO’s
Board members, Bob and me (2016, p. 20).
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This balance was first challenged when Bob and I first arrived at DCO’s
Camp Sunshine Retreat, where we were to present DCO’s vision and strategic
plan to their Board, families and medical advisors. When we arrived at Camp
Sunshine, we were invited to have dinner with the camp families. We agreed
that it would be rude not to interact with the families and we enjoyed meeting
them and learning more personal stories of their coping with DC. This was a
critical part of the personalization process.
The next day, after Bob and I presented the DCO vision and plan to its
members, we were invited to be included in a camp picture with families, doctors
and others at Camp Sunshine. I decided that I was not comfortable doing this. I
felt that the camp and its pictures were to provide hope and encouragement for
those coping with DC, and not a place to memorialize those who had been lost. I
was stuck in-between the role of a consultant who maintained objectivity with our
client and the role of a grieving parent amongst those who were currently
survivors of DC. My relationship with DCO has changed since losing Josh and
even more so now as I’m looked upon as a consultant. I was concerned that
joining in with the families who were celebrating their time together at Camp
Sunshine would create more confusion in regard to these roles. I believe
stepping away at this time was appropriate.
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Determining an approach
Understanding DCO’s history and being familiar with other rare disease
organizations was helpful in evaluating what we believed would be the most
effective approach in structuring our engagement. One option was to follow a
conventional problem-based approach in which we would survey the board for
their objectives, evaluate their present state, develop a gap analysis, and then
help them identify a plan to move forward. From our initial discussions with the
Board, it became clear that there were much deeper challenges to be addressed
if they were to successfully develop and execute a strategy focused on
expanding their capabilities and outreach. Our initial evaluation of the Board and
the organization’s readiness to engage in a more comprehensive strategy
development exercise revealed the following:
Board Fatigue: Like many patient advocacy organizations, DCO had been
built on the energy and commitment of a core group of patients and their
families. None of the current Board members had professional experience
as a non-profit leader and most had limited or no professional managerial
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experience. Commitment, a passion for their mission, and a high degree
of tenacity had fueled their growth and success. After years of supporting
patients and families, while also managing the emotional and physical
challenges of dealing with the disease themselves, many of the Board
members were exhausted and becoming dispirited at the new challenges
they were facing. A growing need for their services, lack of funding and
challenges in raising funds, and lack of success in recruiting more active
engagement amongst the organization’s membership were all areas that
would require vision and energy.
Absence of a coherent vision of the future for DCO: Through our
conversations with the Board collectively and individually, it became clear
that a vision for the future of the organization was lacking. While some
individual members had general thoughts about the organization’s
potential future, most were focused on serving the present needs of their
members. Consequently, collective thought had not been given to the
future. Through discussions, we learned that Board members were so
consumed with delivering services to current and new members –
everything from assembling, packaging and posting informational
welcome packets, to managing the website and social media presence,
and hosting a monthly family teleconference – it was apparent that there
was no time or energy to plan for the future.
Lack of confidence in their skills as organizational leaders: The absence
of formal non-profit managerial skills, training and experience, combined
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with pressures of meeting current needs of members, left the organization
lacking confidence in its own ability to envision a thriving future. It was
critical that they had the opportunity to step-back, assess their current
state and understand the existing internal and external influences that
would enable them to lead the organization on a journey to achieving that
vision.
Lack of a conscious appreciation for what they had already accomplished:
During our initial discussions, we were surprised to observe that there did
not seem to be a conscious awareness of the magnitude of what the
organization had accomplished since it had been founded. As third
parties looking in, we were surprised and impressed to see what a group
of committed patients and families had accomplished with minimal nonprofit training or experience, and relatively small amounts of funding.
Since its formation in 2008, DCO has formally registered as a 501 c(3)
non-profit; established a global patient directory; recruited a medical
advisory board comprised of internationally accomplished researchers in
the field of genetic orphan diseases; grown the organization’s membership
to over 400 members from five countries; held a biennial camp for DC
families; and published a 400+ page medical diagnostic and clinician
guidelines manual. While everyone we spoke with acknowledged these
accomplishments, we did not believe that they fully comprehended the
magnitude and importance of their success. Our initial take-away was “if
they can do this as a layman’s Board with no formal non-profit training,

24

imagine what would be possible if they were able to develop their skills in
leading a mission based organization!”
From these initial observations - Board fatigue, a lack of a future vision,
low self-confidence, low appreciation of previous accomplishments – we
developed a set of priorities that we thought were critical to the success of this
project:
Emphasize the accomplishments of the organization to help build their
self-confidence.
Devise and accompany the Board on a journey of discovery, helping them
to understand how they can leverage the strengths they currently have,
while building new capability with additional training and support.
Help them step back from the day-to-day firefighting, which consumed so
much of their time and energy, to create the perspective to envision the
possibilities for the future of DC Outreach.
Work with the Board to help them prioritize which activities should be
continued, which should be stopped, and to consider who they can enlist
help from in the broader organization to share the workload.
Bob and I were influenced by what authors Sarah Lewis, Jonathan
Passmore and Stefan Cantore present in their book, Appreciative Inquiry for
Change Management (2011) as the “SOAR” model. SOAR is an acronym for
Strengths, Opportunities, Aspirations and Results (2011, p. 189). The strategic
planning process needed to be inclusive and as consultants, we needed to
facilitate a process that was owned by DCO’s leaders and members. We
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decided to incorporate David Cooperrider’s Appreciative Inquiry (AI) model which
is described on Case Western’s Appreciative Inquiry Commons website as:
The cooperative search for the best in people, their organizations,
and the world around them. It involves systematic discovery of
what gives a system “life” when it is most effective and capable in
economic, ecological, and human terms. AI involves the art and
practice of asking questions that strengthen the system’s capacity
to heighten positive potential. It mobilizes inquiry through crafting
an “unconditional positive question” often involving hundreds or
sometimes thousands of people.
(https://appreciateiveinquiry.case.edu/intro/definition.cfm).
With those priorities in mind, we felt that an approach informed by
appreciative inquiry would provide the appropriate framework for creating
momentum and energy for the organization and its leadership, through a
strengths-based focus. We planned to employ an inquiry-based methodology to
focus on strengths and opportunities and help DCO’s Board move beyond
perceived weaknesses and threats (Stavros, Cooperrider, & Kelly, 2003, p.6).
Appreciative Inquiry and DCO consultation
Based on our initial discussions with the DCO Board, our assessment of
the current state of the organization, and the Board’s objectives regarding a
future strategy, we developed an engagement design built on the principles of
Appreciative Inquiry. Although we were not able to convene a more traditional
multi-day Appreciative Inquiry workshop, we were able to use those same
concepts and constructs, while working within the time, geographic, and logistical
constraints we faced. The engagement consisted of four major phases:
1. Stakeholders and Questions: We introduced our engagement process to the
Board during a board meeting. This discussion included an overview of the

26

Appreciative Inquiry approach, a list of proposed questions for interviews and a
rough timeline for the engagement (Appendix A).
2. Interviews & surveys: These included thirty individuals who represented
patients, families, board members, doctors, researchers, leadership from
partner organizations, and the pharmaceutical industry. We also conducted a
prioritization exercise with the Board to agree on a set of questions that we
would use for the interviews and surveys to be conducted with these
stakeholders. Based on discussion with DCO’s Board, we derived the
following sets of questions for three different sets of stakeholders:
DCO Board members, patients and caregivers – this group included
eight current and prior members of DCO’s Board and eleven other DCO
patients and caregivers from the United States, Canada, New Zealand
and Sweden.
a. What are you most proud of that DCO has accomplished?
b. When DCO is at its best, what are the core factors or strengths that
give the organization life?
c. In your ideal world, what does DCO look like five years from now?
d. From your vision of DCO in five years, what do you see as the most
important attributes & skills for its Board members?
e. Partnerships have proven to be very important to DCO. What existing
partnerships should be strengthened and what new partnerships
should be pursued to support the five-year vision?
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DCO Doctors – this group included all six members of DCO’s Medical
Advisory Board and two other doctors who have treated DC patients.
a. What would you consider to be the most important areas for DCO to be
engaged with in the medical and research communities in the next five
years?
b. What non-DC conditions should DCO consider when exploring
possible partnerships?
c. If DCO was able to sponsor research, what areas of research do you
believe would be most important?
DCO Partner Organizations – this group included the leadership of five
rare disease organizations and support groups that included Penn’s
Orphan Disease Center, Global Genes, Camp Sunshine, Smart Patients
and Repeat Diagnostics. In addition to the DCO partner organizations, we
also interviewed a highly respected CEO of an orphan disease
pharmaceutical company.
a. As a partner with DCO, what core competencies and strengths do you
feel DCO contribute and can build upon?
b. How does DCO best compliment your organization and how could they
best expand their influence with you in the coming years?
c. What attributes do other rare disease advocacy groups demonstrate
that have been valuable in growing a successful partnership with your
organization. How can DCO increase their effectiveness in these
areas?
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d. Are there other organizations that you have worked with that you
believe would be a good partner for DCO? Who are they and would
you be open to facilitating an introduction?
3. Synthesis and reporting: Using the data acquired during the interviews, we
assessed and synthesized the feedback, developing key themes for each
major constituency, and then developed recommendations to share with the
Board and present to the DCO community who would be present at one of
their biennial camp sessions at Camp Sunshine in Casco, Maine. The camp
session would also provide the venue for us to facilitate a conversation
amongst the community to help refine our broad strategy recommendations
into a more specific action plan. The key themes for each constituency are
listed in the body of the presentation made at Camp Sunshine (Appendix B).
4. Create a detailed action plan: The final step of the engagement was to
incorporate everything we had learned through all of our interactions with the
DCO community, and create an action plan for the organization to use. We
primarily focused on creating a roadmap of specific activities and milestones
that the Board could follow to kick-start their efforts. The detailed action plan
was delivered to the Board (Appendix C). Along with a detailed action plan we
also provided the Board with a draft of a “Call to Action” memo for their
constituents as well as a draft job description for an Executive Director.
Throughout these interviews and surveys we found alignment in what
DCO members and others had identified as their most profound
accomplishments. Almost every DCO family and medical community member
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interviewed identified the publication of DC’s Clinical Guidelines as their biggest
accomplishment. They also spoke about the ongoing support DCO provides
through monthly parent and patient calls with members of their own medical
advisory committee and others to help families fighting DC. Camp Sunshine and
the simple fact that they’ve accomplished so much with so little were recurrent
themes that members of the DCO community reflected upon in their responses.
DCO members described the organization’s biggest strengths. Strengths
included tremendous commitment from a dedicated and responsive medical
advisory board. They also expressed that DCO was at its best when members
pulled together to help a family under difficult circumstances, and their ability to
work together with a common focus and goal. These strengths were
demonstrated during their participation at medical conferences and building
strategic partnerships to advance their mission. DCO’s board and its members
were aligned in recognizing the valuable work they’ve done on behalf of their
families.
Our interviews and data collection outlined a common vision and
aspirations that included casting a broader net in identifying patients with DC and
those with other telomere biological disorders. It also identified opportunities to
build impactful relationships with the pharma community as well as taking a more
active role in influencing research towards treatments and ultimately a cure for
DC. These aspirations were broken down into four categories as presented
below:
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Members also identified differences and alignments between those who
are adult patients with DC and those who are caregivers, mostly parents that are
managing and living this illness through their children.
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While identifying how DCO would build upon its history of accomplishing
so much with so little, their community also realized that the organization needed
to grow to meet these aspirations. Member engagement, expanding their
network to individuals with valuable skills and commitment that were not as
directly impacted with the disease, and focused fundraising were all aspirations
that needed to be acted upon to build on their success. The vision included
moving from a patient-driven group to an effective professional advocacy
organization and it was agreed that a seasoned Executive Director who could
work with a board focused on DCO’s strategy and a committee structure as
outlined below would be a critical factor towards moving forward.
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Although ambitious, the plan presented generated energy and a sense of
achievability from the Board and DCO members when presented at the Camp.
DCO’s Vice President, Rachel Godfrey, stood up after we presented their vision
and proclaimed that she felt “DCO was so close to meeting these challenges, we
just need those in this room to help!”
As we developed these thoughts and ideas into an articulate presentation,
we began discussing what we thought would be needed for DCO to successfully
move forward. We shared a concern that the current board members did not
have the capacity or experience to organize these ideas into an actionable plan.
We decided we needed to be prescriptive in outlining the tactical steps that the
board would review, prioritize and execute upon. We also provided DCO with a
draft job description for an Executive Director as well as a “Call to Action” to help
them expand upon their member’s engagement. This went beyond the initial
scope of our engagement, but we agreed this would be critical to help DCO move
forward. We discussed this plan with DCO and they were grateful for the
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roadmap we provided. DCO’s President, Robin Huiras expressed this as she
shared the following with us in an e-mail (October 10, 2016):
Hi Bob & Bruce,
Thanks so much for this.
I was thinking today about the qualities that someone would need
to have to run the group (there's so many). And it's so very nice to
have you and Bruce thinking about this for me. It's just so kind of
you and I thank so for your time and energies helping DCO.
You both have given us a vision to work toward. It's not something I
knew was missing, But now that it's there, the path forward makes
so much more sense. Your work and ideas are so appreciated.
Take care,
Robin
Next steps with DCO – coaching a new President
Shortly after we returned from Camp Sunshine, DCO’s president, Robin
called me to let me know she would be stepping down from DCO’s board at the
end of the year. I was not surprised by Robin’s news, as I could see she was
physically and emotionally struggling from the disease while at the camp. Robin
also told me that Katie, someone who had been a less-active board member
whose son received a bone marrow transplant two years ago would be stepping
into the role of Board President. I had interacted with Katie a few times over the
past several years and had met her for the first time at Camp Sunshine. Katie
seemed to have a lot of energy and passion towards helping others with DC. At
camp, Katie and I had a conversation about her desire to be more active with
DCO. She was struggling to understand how she could contribute. I shared with
her some of my thoughts regarding the vision and what would be required to
make it happen. At this time I realized that Bob and I had to help DCO’s Board
members and families find their story. It’s a story many of them already know,
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but we provided a framing to tell it and make it an effective tool in building
resources and energy to make it happen.
After receiving the call from Robin and reflecting on my interaction with
Katie, I realized there was still much I could do to help Katie in her new role and
contribute towards her ability to successfully lead DCO towards their vision. The
next weekend, I reached out to Dr. Russo and shared my thoughts about where
we were in our engagement and how I could continue to be of help to DCO. I
realized that I could not return to DCO’s board, as the reasons I left still remain. I
also realized that I could continue to help in a more focused and targeted way. I
asked Dr. Russo for her thoughts if I moved my relationship from a consultant to
DCO to a coach for their new President, Katie. As we discussed this idea, we
agreed this would be a natural extension of our consulting engagement. When I
approached Katie with this proposal she was very excited and energized to move
forward. We agreed to begin formalizing this arrangement and as I write this
capstone, we are excited to move forward with this engagement. This will serve
as the coaching field experience in completing my MSOD by June 2017.
As I write this capstone, Katie and I are three months into our coaching
engagement. This has provided an opportunity to help Katie see herself as a
leader and define a vision that will enable DCO to continue to build on its
previous successes. This is an especially challenging time for rare disease
advocacy as our country’s new President and his administration are targeting
significant budget cuts towards federal research, namely the National Institute of
Health (NIH). The role of DCO’s leader is even more challenging as it will require
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even greater collaboration with other rare disease organizations, the
pharmaceutical industry and other research centers. Also, as DCO has recently
transitioned this role to Katie, it will be important that they are able to move
forward in their research, fundraising and advocacy initiatives with great urgency,
while keeping DCO’s patients and caregivers front and center. Katie is taking on
this role at an especially challenging time and I have been learning with her as a
coach and advocate.
Following our engagement with DCO, I spoke with other Executive
Directors of nonprofits, friends, colleagues and just about anyone who would
listen to our adventures over the summer. I realized that the DCO story is not an
unusual one. There are thousands of other rare disease and other grassroots
organizations that struggle with thin resources and ever-growing needs. As I
near the end of Penn’s Master’s Program in Organizational Dynamics, I’ve
realized that the nonprofit community is an area that provides enormous
opportunities to utilize many of the skills I’ve learned throughout my career as
well as life experiences and my ongoing education. This has created an exciting
vision that I am currently developing and that this capstone explores further.
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CHAPTER 3
LITERATURE REVIEW
Working with DCO during the summer of 2016 along with my personal
experiences in the rare disease community has inspired me to go further in
understanding and researching the influence of leadership and the role of the
consultant in building organizational capacity and achieving outcomes in small
non-profit organizations with a particular focus on rare disease advocacy.
Building from the experiences and learning of the DCO case study, this literature
review applies these observations to the following areas:
•

Rare disease advocacy organizations –what factors separate these
organizations from other nonprofits.

•

The nonprofit/consultant relationship –what methodologies and
applications are most effective when working with nonprofit
organizations as a consultant and how these relationships have helped
lead these organizations to grow in effectiveness, innovation and
capacity.

•

Leadership and innovation in nonprofit organizations – qualities and
challenges that distinguish the nonprofit sector from for-profit
enterprises.
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Each of these topics are analyzed with the DCO case study in mind and
the case study serves as a data point in comparing and contrasting the theories
and arguments presented.
Rare disease advocacy organizations
Rare disease advocacy organizations, such as DCO share the
commitment and passion that can lead to innovation and increased capacity.
These organizations also have unique challenges when compared to larger
organizations in the nonprofit sector. As demonstrated in the DCO case, Boards
and volunteers of rare disease advocacy organization often consist of patients
and caregivers that are stretched in many ways. One reality that amplifies these
challenges is that the members of rare disease advocacy organizations are
literally fighting for their lives. This leads not only to commitment, but also
urgency. This is often exacerbated as by definition, these groups often lack size,
scale and a forward looking perspective that would enable greater capacity for
strategic leadership and vision. They are truly living their lives and managing
their organizations on a day-to-day and moment-to-moment basis.
Featured in the medical journal Science, Dr. David Fajgenbaum, who’s
inspirational and incredible journey as doctor, researcher and rare disease
patient is described in greater detail in the next chapter of this capstone,
describes his work in fighting Castleman’s Disease. Dr. Fajgenbaum is the
founder and leader of the Castelman Disease Collaborative Network, whose
mission is to prioritize and coordinate research into this disease. Dr.
Fajgenbaum describes his passion as “intensely personal” (Thomas, 2017, p. 7).
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Dr. Fajgenbaum’s friend Josh Sommer describes Fajgenbaum as the
“quarterback” for Castleman’s disease and maintains that “every rare disease
needs… someone to marshal the team, harness the resources, and lay out a
game plan…People have to put their faith in this person” (Couzin-Frankel, 2016,
p. 214). Fajgenbaum’s journey exemplifies just how limited resources are for
rare disease organizations as they address problems that are extremely complex
and are literally life-or-death.
As rare advocacy organizations struggled with limited resources and a
patient base too small to be attractive to those in the for-profit sector to take
notice, transformational change was needed to bring these groups together to
garner attention towards a collective mission. The history of National
Organization for Rare Disorders (NORD) and the Orphan Disease Act offer other
rare disease advocacy groups and those who look to partner with them as
consultants, insight into what makes these organizations special and unique.
NORD is a nonprofit (501(c)(3)) organization dedicated to patient
advocacy and individuals with rare diseases and the organizations that serve
them. NORD’s mission is committed to the identification, treatment, and cure of
rare disorders through programs of education, advocacy, research, and patient
services (https://rarediseases.org/about/what-we-do/history-leadership).
Founded in 1983 through its advocacy of the Orphan Drug Act of 1983, NORD is
the leading rare disease umbrella organization in the United States. Their motto
of “Alone we are rare. Together we are strong,” serves to frame their mission
and vision of:
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•

A national awareness and recognition of the challenges endured by
people living with rare diseases;

•

A culture of innovation that supports basic and translational research to
create diagnostic tests and therapies for all rare diseases;

•

Access for all patients to the diagnostics and therapies that will extend and
improve their lives;

•

A regulatory environment that encourages development and timely
approval of safe effective diagnostics and treatments.
In 2014, the Journal of Orphan Drugs: Research and Reviews, published

A 30-year retrospective: National Organization for Rare Disorders, the Orphan
Drug Act and the role of rare disease patient advocacy groups by Mary Dunkley.
The retrospective recounts the origin of a formalized rare disease community that
was driven by a few-high profile individuals. Two of these individuals were
Marjorie Guthrie, the widow of legendary folk singer Woody Guthrie, who died
from the rare Huntington’s Disease, and actor Jack Klugman (2014, p. 20).
Actor Jack Klugman, who starred in the popular television drama Quincy,
MA was influenced by his brother, Maurice Klugman who was a producer on the
show, and suffered from a rare form of cancer. In 1981, Maurice created a story
depicting a young man suffering from Tourette’s Syndrome and the orphan drug
problem. When the episode aired, it sparked a firestorm of interest, particularly
from individuals and families affected by rare diseases. In describing the episode,
the Washington Post Wongblog depicts the following in an article paying tribute
to Jack Klugman when he died in 2012:
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In a fit of pique, Jack Klugman hit upon a novel idea. He and his brother
wrote a second Quincy episode, this one revolving around an orphan drug
bill that was being held up by a heartless (fictitious) senator. In a pivotal
scene, Quincy confronts the senator in his office and demands that he
look out the window. Peering down, the senator sees a huge crowd
gathered with signs that read “We Want the Orphan Disease Act” and the
Senator relents. To shoot the scene, the show’s producers hired 500
extras who really did suffer from rare diseases…. Hatch (Senator Hatch,
a real-life congressman who was blocking the bill) too relented. Thanks to
Klugman, the Waxman-Hatch Orphan Drug Act became law in 1983. It
has been a remarkable success. The FDA has approved more than 300
orphan drugs, with 1,100 more under development (in 2012).
By definition, each rare disease advocacy organization is an
underrepresented group with critical needs and hopes. Collectively, they
represent over 7,000 diseases and 300 million people. Umbrella organizations
like NORD have brought influence and power with numbers. They facilitate
innovation to rare disease communities, including influence with legislation and
pharmaceutical companies as well as the globalization of resources.
The nonprofit/professional relationship
Recognizing and understanding the unique strengths and challenges
presented to nonprofit organizations informs the practitioner in how to best help
mission-based organizations. Penelope Cagney examines the unique
relationships that consultants and practitioners experience when working in the
nonprofit sector in her 2010 book Nonprofit Consulting Essentials. Cagney writes,
“Nonprofits have a range of consulting needs that differ from those of their forprofit counterparts… They must work with consultants who know how to work
with them – who can use nonprofit strengths to advantage and shore-up their
weaknesses, who respect their uniqueness and are aware of how they differ from
business – consultants who know when it is appropriate to apply for-profit
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thinking but also when it is best to develop their own (2010, p. 1).” Cagney refers
to much of what Peter Drucker has observed in regard to the unique strengths of
nonprofit organizations, she quotes Drucker, “The Girl Scouts, the Red Cross,
the pastoral churches – our nonprofit organizations – are becoming America’s
management leaders. In two areas, strategy and effectiveness of the board, they
are practicing what most American businesses only preach. And in the most
crucial area – the motivation and productivity of the knowledge workers – they
are truly pioneers, working out the policies and practices that business will have
to learn tomorrow” (2010, p. 2).
The DCO case demonstrated that unlocking the inherent passion and
strengths that are found in the nonprofit culture presents a unique challenge to
the consultant. Cagney describes the “… boundless passion found in nonprofits
is a great asset but can also be a handicap. In the extreme it can seem to defy
reason… As a result it is possible for board and staff to view with suspicion
anyone who doesn’t share their commitment” (2010, p. 13). Prior to taking on the
role of a consultant with DCO, I was a member of this community and remain an
advocate as someone who had been directly impacted by this terrible disease.
Although my history with the group and passion towards its mission were not
something I ever felt I had to prove, I understood that my role as a consultant
would be much different than the role of a parent. Part of the challenge
throughout the engagement was to manage myself effectively, listen without
prejudice while still maintaining high levels of empathy and unconditional positive
regard. In Flawless Consulting, Peter Block stresses the power of authenticity in
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the consulting relationship as he writes “… Acting authentically is the most
powerful thing you can do at every stage of the process” (2011, p. 44). Carl
Rogers stresses the power of empathy in On Becoming a Person as he writes
“…if I can form a helping relationship to myself – if I can be sensitively aware of
and accept my own feelings- then the likelihood is great that I can form a helping
relationship toward another” (1995, p. 51). Sorting through my own experiences
and feelings in regard to DC and DCO was an important step in effectively
working with DCO. Cagney’s book addresses the unique relationship of the
consultant with nonprofit organizations.
Cagney’s philosophy often references the humble consulting relationship
as described by Edgar Schein (2016). Schein emphasizes that to truly
understand organizations where problems are complex and ambiguous, which is
especially true in organizations that are measuring outcomes based on their
impact toward mission rather than primarily on dollars and cents, there must be a
degree of “personalization” that the consultant offers and experiences to truly
help an organization (2016, p. 7). In describing personalization, Schein
describes a “Level 2” relationship that goes beyond a transactional relationship
between the consultant and client, but also avoids the trappings of a more
intimate relationship that may go beyond what is truly effective in understanding
and helping an organization. Schein describes the Level 2 relationship as the
consultant not opening the door to anything personal, but rather, creating a
climate where the client will be able to become trusting to a degree where they
may reveal what is really happening within an organization. He characterizes the
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consulting relationship as one that includes a level of personalization, which he
describes as the “fundamental process by which we move from being strangers
to becoming acquainted, getting friendly, being teammates, getting connected,
and in various ways developing the higher level of trust and openness that I am
calling the Level Two relationship” (Schein, 2016, p. 111).
Schein’s approach resonates in regard to the dynamics described by
Cagney as they both encourage the consultant to avoid becoming “content
seduced” (2016, p. 20). Rather, the helping consultant enables the organization
to build its own capacity. Cagney and Schein focus on the consulting process
rather than simply the outcome. This was particularly relevant in the DCO case,
as their needs went beyond problem solving, but rather, they had a more
complex need of building organizational capacity.
“The Future of Organization Development in the Nonprofit Sector”
provides a study that seeks to inform organizational development practitioners in
regard to how they can most positively impact nonprofit organizations
(Wirtenburg, 2007). The article outlines the findings of a survey of 235 nonprofit
executives as well as a dozen corporate leaders seeking their input in regard to
how organization development practitioners could most effectively (2007, p. 180):
•

Align the organizational development field more closely with the
substantive challenges facing the nonprofit sector;

•

Add value by leveraging the strengths organizational development can
offer nonprofit organizations;

•

Blend theory with practice; and
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•

Create a significant and positive impact on civil society by infusing values
and process expertise that are the building blocks of the interdisciplinary
field of organizational development.
The survey revealed that the nonprofit organization leaders identified

development and management of emerging leadership as the most neglected
critical activity in their organizations. Respondent’s specifically mentioned limited
resources, especially funding their organization’s small size, as responsible for
the difficulties in developing leadership capacity. The responses also indicated
that nonprofit organizations must continually change to sustain and achieve their
mission. One respondent wrote, “Determining (and) communicating vision,
observing others in the system as they attempt to translate vision into action,
coaching for action, educating to overcome resistance, identifying the important
dissatisfactions, (providing) reasons for change, and providing ongoing
communication about those dissatisfactions” were all components in driving
sustainable changes to meet nonprofit missions” (2007, p. 185-186).
The themes of leadership, innovation and transformation, vision and
collaboration are common throughout the literature focused on helping nonprofit
organizations. Although none of these attributes or outcomes are unique to
nonprofits or rare disease advocacy organizations, this sector is challenged at a
higher degree than many of their nonprofit counterparts. Not only by size and
skill levels within the organization, but as was demonstrated in our work with
DCO, just talking about the disease was difficult for those directly impacted by
DC. Demonstrating empathy and positive regard proved to be of even greater
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emphasis when working with a rare disease advocacy organization. This was
particularly challenging while maintaining a professional and consultative
relationship between the organization and the consultant. When planning the
DCO engagement, Dr. Russo, Bob Biglin and I recognized this as a particular
challenge and agreed that focusing an engagement on vision and Board efficacy
would be a useful strategy in avoiding the overwhelming and morbid realities that
rare disease organizations must overcome.
Analyzing the effectiveness of employing an Appreciative Inquiry approach
The DCO engagement centered on building a strategic plan that would
enable DCO to grow its internal capacity and further deliver on its mission. As
we evaluated approaches in working with DCO, Bob Biglin and I both had
developed a foundational philosophy based on a humanistic approach to
consulting. During our initial conversations with DCO’s board, we understood
that the Board was very much caught in the moment in meeting the needs of
their constituents. They lacked the capacity and objectivity to take a step back
and evaluate their strengths, what they had accomplished, and what challenges
they would encounter in continuing to move DCO’s mission forward.
From our initial discussions with the Board, it became clear that there
were much deeper challenges to be addressed if they were to successfully
develop and execute a strategy focused on expanding their capabilities and
outreach. From these initial observations which included observing board
fatigue, a lack of a future vision, low self-confidence, low appreciation of previous
accomplishments. We felt that an approach informed by Appreciative Inquiry
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would provide a productive framework for creating momentum for the
organization and its leadership, through a strengths-based focus. This approach
has been the subject of evaluation and analysis since Cooperrider introduced the
world to his Appreciative Inquiry model.
When is Appreciative Inquiry Transformational? A Meta-Case Analysis
(Bushe, 2005) and Comparing Appreciative Inquiry to Action Research: OD
Practitioner Perspectives (Egan, 2005), are two articles that provide a strong
foundation to understand when and how AI has been successful as well as its
limitations.
When Is Appreciative Inquiry Transformational? A Meta-Case Analysis
presents a series of case studies that evaluate whether an AI intervention has
resulted in transformational change. In determining if each case was
“transformational,” the analysis considered whether each case included the
following two key outcomes (2005, pp. 163-164):
1. Did the AI intervention result in new knowledge or as more
typical traditional OD and change management on new ways
of doing things? Did it create one or more new lenses
(images, models, theories) for looking at old issues?
2. Did a “generative metaphor" emerge out of this initiative? A
“generative metaphor” is defined in this article, as “sayings
or phrases that are in themselves provocative and can
create new possibilities for action that are not previously
considered.”

The twenty cases examined focused on specific initiatives within
departments or subsidiaries of large companies. It found that 35% of the
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examined cases using an AI approach resulted in what the authors defined as
“transformational” change.
Comparing Appreciative Inquiry to Action Research: OD Practitioner
Perspectives examines the assumptions, approaches and implications of AI and
AR for organizational development (OD) from the perspective of OD
practitioners. The study includes interviews with OD practitioners to explore the
strengths and weaknesses of AI compared to those of AR (Egan, p.29). The
authors provide qualitative data that highlight the strengths and weaknesses of AI
and AR approaches and summarize key items as follows (2005, p. 41):
AI Strengths

AR Strengths

AI Weaknesses

AR Weaknesses

Refines
understanding
about
organizational
capacity

Empowers employees
and stakeholder to
actualize change

Difficult interpersonal
situations may be
overlooked

Process may not
thoroughly empower
participants in the
process to examine the
breadth of organizational
capacity

Helps to override
previously difficult
events

The process can be
transferred to the
client for independent
use

Dissatisfied organization
members may withdraw
from the process

A clear exploration of
available opportunities
could be overshadowed
by negative perceptions
or feelings

Empowers
employees to
connect
interpersonally

It is iterative or
repeating allowing for
continuous
improvement

Employees may become
frustrated with managers
and executives unwilling
to discuss important
challenges being faced
by the organization

AR keeps the
organization moving
from one unsolved
problem to another.

Each of these studies stand on their own; however, they are intertwined
and impactful in regard to considering the effectiveness of an AI approach as
compared to the more traditional organizational development approaches such
as action research.
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Busche’s meta-case analysis seeks to determine if AI leads to
“transformational” change. It does not explore in great depth why this may or
may not be the case. Busche does not denigrate AI as ineffective when a
transformational change is not achieved, and recognizes that each individual
case and the nature of the problem itself may be more or less determinates of
what is actually transformational (2005, p. 177-178). Whether the AI process
facilitates improved organizational learning and performance reaches the
standard of “transformational” is not clear in this analysis. It also is not clear
whether a 35% rate of achieving transformational change compares positively or
negatively to alternative approaches. It is worth questioning and following up
with the 35% of the case studies that did achieve a form of transformational or
significant change. It would also be worth exploring whether these results were
sustained any better or worse than a similar set of cases using alternative
organizational development approaches.
Schein’s Humble Consulting model demonstrates an emphasis on
equipping the organization with the ability to generate a series of more modest
yet impactful adaptive moves rather than bold and obvious transformational
outcomes. Schein writes, “If the problem turns out to be complex… the client
and helper should engage in a dialogue to figure out a feasible adaptive move,
knowing that this may not solve the problem but will provide some comfort and
will reveal new information on the basis of which to figure out the next adaptive
move.” He continues, “My clients and I will discover that the first real help is my
enabling them to see the true complexity and messiness of the problem situation
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and help them to abandon the quick fixes and/or knee-jerk reactions. Beyond
that, the real help will be to evolve the right adaptive moves to deal with the
realities of the situation that I help them to identify” (Schein, 2016, pp. 23-24).
Schein’s approach is relevant in generating more sustainable outcomes and
enabling the organization to grow by building its own capacities. These are
critical factors to the success of building a strong and agile nonprofit
organization.
In the case of our DCO case study, it is too soon to determine if a
transformational change within DCO has occurred as a result to our AI
intervention. Although we implemented an AI approach with DCO, we also
consciously deviated from a pure AI approach as we felt we needed to be more
prescriptive than not in providing an action plan to the organization rather than
facilitating them through the development of their own plan. This was a function
of both time and an assessment of the current organization’s strengths and
competencies. The overall result of the DCO engagement was to provide an
action plan that focused on organizational structure and milestones to enable
DCO to achieve transformational changes in its future, but not necessarily to
achieve this change through the intervention. It would be interesting to
understand what and if incremental changes from the AI or alternative
interventions examined in Busche’s analysis occurred prior to the
transformational changes that he’s quantified in his study.
Whereas Busche’s meta-case focuses on AI outcomes, Egan’s
comparison between AI and AR focuses on the strengths and weaknesses of
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alternative processes. Egan introduces the idea of whether AI could effectively
be included with AR or other problem solving approaches. Egan offers two
perspectives from practitioners he interviewed for his study (2005, p. 44):
“We need to embrace the philosophy behind AI, not just use part of it” and,
“It is important that the strength of AI be tapped, but it is also recognized
that in some cases it is a consulting approach that can be used in
conjunction with other approaches.”
Egan studies the benefits and limitations of the AI approach as compared
to other approaches. He is not focused on the outcomes of these interventions
as Bushe explores. Egan demonstrates that the process is just as critical in
facilitating the capacity and growth of the organization to optimize and exceed its
current state, as is the outcome of the specific engagement.
Problem solving and challenges facing the organization were not ignored
as the DCO engagement evolved. However, they were not the main focus
towards providing consultation and help. Consistent with the AI process, we
worked with the Board and other DCO stakeholders to gather data and articulate
their vision. Our approach was influenced by the philosophy offered by Edgar
Schein in his book Helping, as Schein writes, “At the beginning of any helping
relationship, and throughout its life, what is crucial is not the content of the
client’s problem or the helper’s expertise, but the communication process that will
enable both to figure out what is actually needed“ (2011, p. 66). Egan’s analysis
comparing AI and AR examines this process between alternative techniques
whereas, as our case study demonstrates, a predominant philosophy and
process may exist, but there is judgment and deviation exerted through its
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application. No one size fits all, rather it is incumbent on the consultant or
organizational development practitioner to understand what approach or
approaches are most appropriate and tailor a blending of these philosophies to
best serve the client. This is achieved through the personalization process that
Schein describes in Humble Consulting (2016).
Examining whether AI translates into transformational or incremental
changes in an organization may not be practical within the scope of this
capstone. However, measuring where DCO’s Board was in regard to its vision
and capacity before and after our intervention may be an indicator of the potential
learning and transformations they’ve enabled by building their capacity.
Implementing an AI approach with appropriate variations appeared to be an
effective way of helping DCO gain energy and momentum from their historic
successes as well as outline a collective vision towards their future.
Leadership and Innovation in nonprofit organizations
Comparing nonprofits with for-profits offers interesting insight in its
application to the DCO case study. Through the strategic planning process,
DCO’s board and constituents collectively articulated a vision that would expand
its capacity and ability to deliver its mission to a wider patient population.
Through this process it became apparent that to move this vision forward, DCO
would have to reengineer its board structure and attract others from within and
outside of the immediate DC community with committed passion and relevant
skill sets to focus on specific areas of patient advocacy and support. Another
critical element to DCO’s vision was the need to recruit, fund and develop the
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Executive Director position to transform DCO from a patient group to a
professional advocacy organization. Like other nonprofit organizations, DCO
would have to balance its passion and mission with the governance, skills, and
leadership attributes that are more commonly found in the for-profit enterprise
sector.
In 1989 the Harvard Business Review published Peter Drucker’s What
Business Can Learn from Nonprofits. Drucker’s popularity and HBR’s wide reach
removed some of the stigma associated with nonprofit organizations as they’ve
often been perceived as inferior to their for-profit counterparts in terms of
business sophistication and organizational capacity. Others have followed
Drucker’s article with more in-depth empirical research and case studies
specifically focused on nonprofit leadership and efficacy.
In Drucker’s 1989 article, he examines how nonprofit organizations have
become more prominent and illustrates a number of advantages nonprofits have
leveraged that for-profit enterprises wish they could emulate. He points out that
for nonprofits, money is a tool rather than an outcome as it is with for-profit
enterprises. He also illustrates how successful nonprofit organizations’ focus on
mission rather than financial outcomes are more difficult to measure, but also
have created levels of sophistication in nonprofits that would be beneficial to forprofit entities. Drucker writes, “Starting with the mission and its requirements
may be the first lesson business can learn from successful nonprofits. It focuses
the organization on action. It defines the specific strategies needed to attain
crucial goals. It creates a disciplined organization. It alone can present the most
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common degenerate disease of an organization… splintering their already limited
resources on things that are “interesting” or look “profitable” rather than
concentrating on a very small number of productive efforts (1989, p. 3).”
Drucker’s focus on the role of a nonprofit board and their CEO or
Executive Director is relevant to recommendations in the DCO case study. As a
CEO from a rare-disease pharmaceutical company emphasized in an interview
that was part of DCO’s strategic planning process explained, “An effective
Executive Director will transform the grass-root patient-driven group to a
professional advocacy organization.” Drucker points out the dynamics of the
relationship between non-profit CEOs and their Board counterparts as he writes,
“Nonprofit organization CEOs complain that their board “meddles.” The
directors, in turn, complain that the management “usurps” the board’s function.
This has forced an increasing number of nonprofit organizations to realize that
neither the board nor CEO is “the boss.” They are colleagues, working for the
same goal but each having a different task. And they have learned that it is the
CEO’s responsibility to define the tasks of each, the board’s and his or her own”
(1989, p. 4). This was a point of emphasis throughout the DCO case study as onboarding an Executive Director who reports to and works independently from the
Board will be a critical success factor in building DCO’s capacity and resources.
Another area that Drucker addresses is community engagement and
training. He emphasizes the importance of a clear mission and providing
members and volunteers with the training and resources to enable them to
effectively engage and add value to the organization. Drucker understands that
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volunteers and employees, who may have sacrificed some of the drawings from
the for-profit sector, do so as they often find self-fulfillment and value by working
for a mission important to them and that will often help others. As Victor Frankl
writes in his teaching of existentialism and finding meaning, “curing the soul by
leading it to find meaning in life” (1963, p.7) is often the motivation of those that
choose to engage with nonprofit, mission-based organizations. Drucker
characterizes this as moving from a force of nonprofit volunteers to one of unpaid
professionals. He writes, “What the nonprofit contribute to the volunteer is as
important as what the volunteer contributes to the nonprofit” (1989, p. 6).
Drucker emphasizes that volunteer professionals are not satisfied with just being
helpers, but they thirst for much more and desire. Many nonprofit volunteers are
knowledge workers in their own profession and they wish to be the same in their
contribution to society. How nonprofits are able to leverage these dedicated and
compassionate resources into innovation and transformational change that drives
growing organizational capacity in the nonprofit sector is the subject of research
and analysis that had followed Peter Drucker’s article.
Inspired by Peter Drucker’s work, Frances Hesselbien, a Girl Scout Troop
leader in York, Pennsylvania implemented Drucker’s philosophies with her local
troop. Her success in doing so caught the attention of the Girl Scouts of the USA
organization, and she became its CEO in 1965 where she grew the Girl Scouts to
a membership of over 2.25 million members and 780,000 employees until she
was recruited by Drucker to run his Leader to Leader Institute in 1976.
Hesselbein, now 102 years old continues to lead this organization, now named to
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Frances Hesselbein Leadership Institute, where she remains their CEO (Leahey,
2011). In her video Frances Heisselbein on Her Journey with Peter Drucker,
Hesselbein shares her first interaction with Drucker in 1968 as she recalls him
addressing her Girl Scout organization by saying, “You do not see yourselves
“life-size”; you do not appreciate the significance of the work you do. Society
pretends to care for its children and it does not. For a little while you give a girl a
chance to be a girl in a society that forces her to grow up too soon.”
Hesselbein’s and Drucker’s relationship continued to grow and Hesselbein
recalls an interview with Drucker in the New York Times where Drucker says that
the Girl Scouts are the best managed organization in the country. The
interviewer interjects, “you mean in the nonprofit sector” and Drucker corrects
him clarifying that they are “simply the best in any sector, anywhere” (Hesselbein,
2011). Hesselbein’s Leadership Institute’s homepage describes its mission as to
“strengthen and inspire the leadership of the social sector and their partners in
business and government by connecting the public, private and social sectors
with curated resources and relationships to serve, evolve and lead together. By
fostering in 1) the passion to serve; 2) the discipline to listen; 3) the courage to
question; and 4) the spirit to include, we work to create an open, responsive,
global social sector.” (http://www.hesselbeininstitute.org/about_us, accessed
February 9, 2017).
Drucker’s philosophies and Hesselbein’s application of these demonstrate
many of the qualities and challenges that were experienced during the DCO
engagement. DCO’s needed to take a step back and acknowledge the
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tremendous work they had produced and celebrate these successes. Building
organizational capacity by seeking specific skills that are fueled with passion
from finding meaning from their mission will help them find those from inside and
outside their immediate community contribute their skills to the organization.
Researchers have gone further to examine the specific nonprofit sector attributes
and leadership qualities that are most effective in this sector.
Australian Management professors, James Sarros, Brian Cooper and
Joseph C. Santora in their 2010 Leadership & Organizational Development
Journal article Leadership vision, Organizational Culture, and Support for
Innovation in Not-for-profit and For-profit Organizations took Drucker’s ideas a
step further. They examined and compared the relationship of nonprofit
organizations’ social consciousness with the competitive motives found in forprofit enterprises. They compared each sector’s ability to leverage these different
motives to build upon leadership, vision, innovation and organizational strength.
Their study found that for nonprofits, a socially responsible cultural
orientation mediates the relationship between leadership vision and
organizational support for innovation. Alternatively, in for-profit companies, a
competitive cultural orientation mediates this relationship. Their research
includes interviews with nearly 1,500 Australian managers. The study found that
socially responsible cultures enhance the impact of visionary leaders on
innovation for nonprofit organizations, while competitive cultures have the same
impact on for-profit enterprises (2010, p. 301). This research is important in
regard to building strategies for building innovative and sustainable organizations
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in the non-profit sector (2010, p. 291). Sorrow et al., write;
The capacity of leaders to define a vision for their organization is one
thing, but to have that vision accepted and acted upon as anticipated both
individually and organizationally is quite another proposition. Additionally,
on the basis of these findings, the formulation and then implementation of
vision is a considerably different proposition in for-profit versus nonprofit
organizations. We propose that nonprofits are more likely to benefit from
leader vision that encourages “buy in” to a set of principles that have
social as well as economical implications and which run counter to the
commercial imperatives of private enterprises. The study illustrates that
organizational cultures play a major role in determining the impact of
leadership vision on organizational leadership (2010, p. 301).
This was demonstrated in DCO’s strategic planning process, as their
constituency looked to the Board to chart the course for DCO’s priorities and
leadership’s abilities to build upon research, collaboration and patient support
and wellness. The process also demonstrated that although the Board and
members of DCO understood and acted on a common mission, they did not have
the ability in regard to their perspective or capacity to step away and create a
story they could share within and outside of their constituency. DCO had not yet
fully utilized the strengths of their mission and vision to drive further innovation or
impact to serve their growing constituency. The strategic planning process
helped create awareness within DCO that a vision was needed and leadership at
the Board would need to transition focus to help articulate and drive vision while
a future Executive Director would be needed to implement that vision and lead
the tactical operations of their organization.
Sarros’ work was informed by the 2004 Nonprofit Management and
Leadership journal study, Transformational Leadership, Organizational Culture,
and Innovativeness in Nonprofit Organizations written by Kristina Jaskyte from
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the University of Georgia’s School of Social Work. Jaskyte’s exploratory study of
leadership organizational culture and organizational innovativeness in nonprofits
sampled 250 employees of the Alabama branch of the Association of Retarded
Citizens (ARC), an organization that represents over 140,000 individuals with
developmental disabilities (Jaskyte, 2004). Although this survey is limited to one
organization, the ARC is similar to many rare disease advocacy groups, including
DCO. Many DCO patients are impacted with mild to severe cognitive disabilities
and many of the same characteristics of the ARC population are shared with the
physical and cognitive impacts of rare diseases.
Jaskyte defines innovation as the ability of organizations to implement an
idea, service, process, procedure, system, structure or product new to prevailing
organizational practices (2004, pp. 158-159). Jaskyte’s research examines the
correlations between the ARC’s capacity to be innovative with characteristics
implicit with what is defined as transformational leadership. Jaskyte defines
transformational leadership as a set of practices employed for developing
relationships between leaders and employees. She defines organizational
culture as the set of shared values that help organizational members understand
organizational functioning and thus guide their thinking and behavior. These
themes are central to the DCO case study as the success of implementation of
DCO’s strategy and shared vision is determined to be influenced in large part by
its ability to transform its board and leadership role to one less centralized that
will build capacity and drive innovation across its mission. These concepts are
innovative to DCO as it has not worked within a shared governance model in the
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past and will need to garner the resources of its members, partners and their
contacts to continue to grow in meeting the expanding needs of their
constituency.
Similar to Sarros, Jaskyte’s study demonstrated that leadership practices
that include “inspiring a shared vision,” “enabling others to act,” “encouraging the
heart” and “modeling the way” were positively correlated with cultural consensus.
However, the study also surmised that a strong cultural consensus characterized
by stability and team orientation actually had a negative correlation with
organizational effectiveness and innovation (2004, p. 162). The idea that
innovation and effectiveness is enhanced by a degree of conflict is important as
DCO’s Board transitions many of its decision-making and implementation
processes to more regionalized committees and Board sub-committees focused
on specific areas impactful to their mission.
Although the data suggests that building a strong collective vision that is
lead by DCO’s board is counter to increasing their capacity, these factors are
much more complex. What Jaskyte’s analysis does support is that leaders must
enable and empower others within the organization to create vision and
contribute towards innovation in their own areas, rather than take a top-down
approach in creating tasks and imploring action. Creating a sub-committee and
regional branches of DCO will be catalysts in building DCO’s member and nonmember engagement as well as expand their capacity. For this approach to be
successful, DCO’s board must move from one that leads with a top-down or taskoriented approach to one that enables innovation at the sub-committee and local
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levels. As Jaskyte cites in a 2001 article, A Strong Cultures and Innovation:
Oxymoron or Opportunity, by authors Flynn and Chatman, “While some authors
see strong culture impeding creativity, others argue that when the right values
are widely shared, a culture will activate creativity and innovation” (2004, p. 163).
Moving from a small group of doers that provide a single voice to DCO’s
constituents to a model that facilitates shared leadership across the organization
will be transformational to DCO. It is a key success factor in their ability to grow
their capacity and continue to deliver to its constituents with efficacy. Peter
Drucker writes that organizations characterized by deeply embedded leadership
practices and organizational values risk success because they can stop
questioning the need to change and respond to the external environment. With
growth and success, DCO finds itself in a place where their “reality has changed,
but the theory of the business (or mission) has not changed with it” (1994. p. 98).
Drucker’s works are relevant as DCO is no longer focused on a small patient
group or limited research. They are becoming a much more impactful
organization as demonstrated with their ability to influence research, increase
clinical access, develop a prestigious medical advisory board and publish clinical
guidelines which have been transformational to its members. They’ve gotten
much larger in their accomplishments and to continue this trajectory they must
move from a small-centralized cadre of leaders to a leadership model that is
disbursed throughout their organization.
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Conclusions from a review of the literature
Understanding the dynamics, strengths and challenges inherent in
nonprofit organizations, and rare disease advocacy groups particularly, is an
important element of equipping a consultant with the correct framing of how to
best help these organizations. As described by Peter Drucker and demonstrated
with case studies and surveys, nonprofit organizations bring the strength of
compassion and mission that for-profit enterprises are envious to emulate.
Familiarizing oneself with the brief history of rare disease advocacy also provides
the consultant with a greater perspective of what unique characteristics and
challenges their constituencies face and how they respond. The literature
documents how leveraging leadership that is fueled with a mission and vision is a
powerful tool for rare disease boards and executives to influence innovation and
both transformational and adaptive changes for these to meet the challenges
they face with limited resources. Applying an Appreciative Inquiry philosophy
with appropriate critical analysis and some level of prescriptive acts to
supplement for areas where DCO may have lacked skill or capacity appeared to
be an appropriate approach in helping DCO enable its Board and members to
create a vision and plan that will help them build capacity and resources to
support the research and wellness that impact their members.
The AI literature demonstrates that applying this approach to an
organizational development consultation was transformational for the DCO
Board. This approach helped them recognize their strengths, accomplishments
and opportunities.
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CHAPTER 4
RESEARCH METHODOLOGIES, ASSUMPTIONS, DATA AND ANALYSIS
Research methodologies and assumptions
The mission of rare disease advocacy organizations is often life-or-death
for its members as they focus on helping and supporting those who are very sick.
As a parent, advocate, former board member and now as consultant to a rare
disease organization, I have seen the passion and emotion inherent within a
“kitchen-table” organization both propel and limit the capacity and effectiveness
of an organization. Based on my experiences, I thought most, if not all, rare
disease organizations ran on a shoestring budget and each struggled to fund and
execute their missions. I assumed what was not present in skills and experience
was compensated for in drive and determination. I also believed a strong Board
and paid professional Executive Director were must haves for organizations to
meet the needs of their constituents and influence research and resources
towards those they advocate. Through the stories of others, I’ve found some of
these assumptions, to various degrees to be true, while others were not the case.
Over the past three years, in large part through participation with the
University of Pennsylvania’s Orphan Disease Center’s Million Dollar Bike Ride
and Rare Disease Symposium, I’ve met other leaders in the rare disease
advocacy community. Those included in this interview process were some of the
most innovative and passionate people I’ve ever met. In addition to those in the
rare disease community, I had the opportunity to interview the Executive Director
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of a special needs camp that serves many from the rare disease community.
Each of those I’ve interviewed shared insights, ideas and experiences. I am
honored to be able to include the following individuals amongst those who
participated in this journey:

Kyle Bryant – an athlete, speaker and
the spokesperson for the Friedreich's
Ataxia Research Alliance (FARA).

(FARA, 2017)

Kristin Smedley – a mother and
advocate for two sons afflicted with
CRB1-LCA, a rare disease diagnosed in
less than 300 people in the United
States. Kristin is a tenacious advocate, a
popular speaker and well recognized in
the rare disease community.

(CRB1.org, 2017)

Dr. David Fajgenbaum – a patient,
advocate, physician and faculty
member at the University of
Pennsylvania. Dr. Fajgenbaum
learned that he suffered from
Castleman Disease, a rare
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inflammatory disorder that causes
hyper-activation of the immune
system.

(CDCN, 2017)
Anne Catlin – Executive Director of
Bournelyf Special Camp. Bournelyf
Special Camp is a summer educational
and recreational day camp in West
Chester, PA, for youth with intellectual
disabilities and related disabilities.

(campbournelyf, 2017)

Robin Huiras & Lisa Helms-Guba –
DCO’s past President and current
Treasurer. Both Robin and Lisa are
DC patients and have shared their
knowledge and experiences with
others within and outside of the DC
community. They are both a testament
to courage, love and empowerment.

(dcoutreach, 2017)

(Annie with her baby in first row)
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Each person interviewed was asked the same series of questions, their
answers and responses were open-ended and invited further probing and inquiry
during each interview. Below is a list of the questions asked, what the underlying
purpose was for each question and my own assumptions, right and wrong, that
were present during these interviews.
•

Describe your journey from when your organization was first formed to
where they stand now.

This question was designed to understand the story of their organization. It
included their involvement as founders or later members. Understanding
where the organization started and their trajectory forward was valuable in
seeing what resources were essential in building a successful advocacy
organization.
My own assumption was that rare disease organizations typically began with
very limited resources and little sophistication in regard to experiences and
skills essential to effectively implement their missions.
•

What do you consider its most impactful successes/greatest
accomplishments?

This question was asked to understand what types of accomplishments
leaders felt were most valuable.
I assumed that leaders would focus on patient support and research.
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•

What contributed to these successes? What 2-3 things were most
critical?

This question was asked with a focus on what skills sets were essential in
regard to creating transformation or innovation in a nonprofit.
I assumed that leaders would identify financial and high profile achievements
that were geared towards curing or bringing wide-scale attention to their
mission.
•

What challenges lie ahead for your organization?

This question intended to learn of the areas of focus for vision and capacity
building for each organization represented.
I assumed a wide variety of vision as each organization was at a different
point in their evolution.
•

What would you consider as transformational to your organization? This
can include things that have already happened as well as what may lie
ahead.

This question searched to understand what leaders viewed as
transformational and how they viewed smaller, adaptive, steps on the way.
I assumed each leader would have a different definition of what was truly
transformative to their organization.
•

Has your organization at any time used a consultant? If so, what were the
most and least effective aspects of the consulting engagement?
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This question was designed to understand the effective or detrimental
aspects of engaging with a consultant and why rare disease or grass-root
organizations were different than more traditional organizations for
consultants. It was also intended to gain perspective on why an appreciative
approach and humble consulting methodology would or would not be most
appropriate for these organizations.
I assumed that not all organizations had used consultants, but those that had
would have experienced successes with a collaborative and personalized
approach between the consultant and the leadership of the organization.
Similar to the appreciative inquiry approach employed during DCO
engagement, these questions are designed to celebrate the accomplishments,
identify opportunities and articulate a vision for each of the subject matter experts
interviewed.
Data
Each of those interviewed had a unique and courageous story to tell.
They share attributes of strength, passion, courage and leadership. Although
each of their stories are different and their respective organizations are at various
places in their journey, their focus on service and their desire to make a lasting
impact that will improve and extend the lives of their constituents brings them
together. An aggregation of the data from these interviews is presented in
Appendix D, below is a brief presentation regarding each journey, from patient or
caregiver to advocate to nonprofit leader.
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Kyle Bryant – Friedreich's Ataxia Research Alliance (FARA)

Ten years ago, at the age of 25, Kyle was diagnosed with
Friedreich’s ataxia. Friedreich’s ataxia (FA) is a debilitating, lifeshortening, degenerative neuro-muscular disorder. About one in
50,000 people in the United States have Friedreich's ataxia. Kyle was a strong
athlete who excelled in baseball and enjoyed outdoor activities. Shortly after
receiving his diagnosis in 2007 he and his family felt that fundraising was a way
they could feel a sense of empowerment as they were faced with Kyle’s new
diagnosis. Kyle soon developed an interest in a recumbent bike and within a
year ventured to ride across the country with his father. Kyle’s mom followed in
the family car and his first ride garnered local and national attention. Kyle is an
incredible speaker and inspiration to others within and outside of the rare disease
community.
In 2009, Kyle joined the FARA Board and is currently the Director of
rideAtaxia and a Director on the FARA Board. FARA’s Board was strong from its
inception as its founders included the retired CEO of Outback Steakhouse, a
retired US Congressman and professionals in the communications, financial and
legal fields. These skills have been valuable in setting their mission and focus
as they continue to grow. Kyle emphasizes the Boards ongoing capacity as
being built one relationship at a time. Setting realistic expectations and a
constant focus on mission and values has helped steer FARA to its current level
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of efficacy and they are positioned well to influence further research and provide
support to their constituents.
Kristin Smedley – Curing Retinal Blindness

Kristin is the mother of two boys affected with a
mutation of the CRB1 gene. A condition diagnosed in less than 300 patients in
the United States and fewer than 1,000 patients globally. Her involvement
started when she learned about a clinical trial that a larger “umbrella” disease of
which CRB1 is related. When learning of this trial, she knew her children and
others with the CRB1 mutation needed to be included and through “stalking” and
persistence, she successfully advocated with fundraising and leveraging the local
and national media. Kristin is known to be a consistent force at rare disease and
optometry conferences. She is a professional speaker and exudes great energy
in her work to create awareness for the CRB1 condition and advocating for a
high standard of life for those impacted with blindness.
Dr. David Fajgenbaum – Castleman Disease Collaborative Network
As a medical student at the University of
Pennsylvania’s Perlman School of Medicine David
was faced with a sudden and life-threatening
episode that included his organs shutting down and
the real prospect that he would not survive what
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was then an unknown condition. Three other times he’s had near-death
experiences from the rare immunological disorder, Castleman Disease. In
addition to being a patient advocate, David is also a physician and faculty
member at the Perlman School of Medicine. David also completed his MBA at
Penn’s Wharton School and was the quarterback at Georgetown University when
an undergraduate student. In 2012 David partnered with the Castleman
Awareness and Research Network, which had been founded in 2007and merged
this existing organization focused on patient support and wellness with his newly
founded Castleman Disease Collaboration Network (CDCN), which would
dedicate its mission towards research. David’s experiences in science, business
and the nonprofit organization he started at Georgetown to help students cope
with grief (David lost his mother while an undergraduate student) served to
implement a plan of collaboration and outreach that has set a model for the
prioritization of research efforts throughout the world. David has dedicated his
life and has offered himself as the personal clinical subject which has advanced
treatment and research in this rare disease. He’s an excellent speaker and has
recently been featured in the New York Times, the medical journal Science and
other local and national news outlets.
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Anne Catlin – Bournelyf Special Camp

Annie & her older brother Joey at a
Bournelyf event

Anne has been the Executive Director of Bournelyf Special Camp for the
past ten years. Bournelyf’s mission of promoting independence, support and
friendship serves 150 campers and their families each year. Camper’s range in
age from seven to several campers in their thirties and forties. Anne, a special
education teacher and mother of two, has been a volunteer, counselor and staff
member at Bournelyf since her older brother Joey started as a camper more than
twenty years ago.

Bournelyf is a special organization to me as my son Josh

attended the camp during the last four years of his life. Since Josh’s death I
have served on Bournelyf’s Board of Directors and our family has volunteered
during the summer camp session as well as other events throughout the year.
Although not focused on rare disease advocacy, Bournelyf serves as an
excellent example of a grass-root organization that has grown in capacity and
impact since it’s inception thirty-five years ago. Campers and families have
found support and identity with others struggling with Downs Syndrome, autism
and other cognitive challenges. Anne has been pivotal in their growth as she is a
highly networked and knowledgeable Executive Director who has effectively
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relied on a strong Board to steer and promote the camp’s mission as it has
evolved with a changing special needs environment.
Robin Huiras and Lisa Helms-Guba – Dyskeratosis Congenita Outreach,
Inc.

Robin (left), Lisa (right)
with Dr. Sharon Savage

Robin Huiras and Lisa Helms-Guba are both DC patients and strong
advocates to the DC community. Robin had been DCO’s President since 2012
through 2016. She is a mother of two and a journalist living in Minneapolis,
Minnesota. Robin has brought her reporting and communication skills to DCO as
she founded their newsletter and ensures they speak with a common voice. Lisa
has been DCO’s Treasurer since 2011. She is a retired nurse in the US Air
Force and mother of a teenager in Annapolis Maryland. Lisa brings a strong
medical and scientific background to DCO and is a tireless advocate with an
appreciation of strong governance and training. Working together with DCO’s
other Board members, they have transformed DCO from a small patient support
group to an advocacy organization that has assembled a top-notch medical
advisory board, published a 400-page clinical guideline book that is an extremely
valuable resource to patients and doctors, influenced research with clinical
application for DC and other biological telomere disorders and fostered a warm
and powerful patient community that is focused on outreach and support. They
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recognize DCO has come a long way and have set a foundation for the
organization to continue to provide resources and support for its growing base of
members. Both Robin and Lisa are fearless and relentless as they manage their
own health challenges every day along with other family members impacted by
DC. In addition to being valuable friends and supporters through Josh’s hardest
days, they have been incredibly generous in their time and insight towards their
contributions in this capstone.
As I interviewed each person, I was in awe of his or her individual story.
Each person shared openly and each agreed that his or her story should not be
masked with anonymity. Each provided generous insight, emotion and feeling as
they discussed their passion and commitment towards their individual and
collective mission. What follows is a summary of the data collected by each
individual for each question asked. This compilation of data is followed by an
analysis that presents common themes and unique ideas as they relate to the
topics of:
•

Building board capacity;

•

moments or changes that were transformational or adaptive to their
organization;

•

collaboration; and

•

their experiences working with consultants.
I was truly blessed with a rock-star line-up of advocates and leaders and

I’m honored to share their thoughts and visions.
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Analysis
Through inquiry and subsequent discussion, each nonprofit leader shared
their own story and their vision towards the future. Although each story was
unique and perspectives differed, there were common themes that ran across
each of the nonprofit organization experiences. Topics addressed within the
interviews included building board capacity and staying focused on mission, the
role of the patient or caregiver, the importance of collaboration and how each
organization has worked to fund and influence research.
•

Building Board Capacity
Building board capacity and recruiting the support of others was a

common theme with each leader interviewed. This was addressed as a factor of
success and accomplishment as well as a critical challenge to meet the future
needs of the organization. In the case of FARA, Kyle Bryant described a very
detailed and deliberate process of Board recruitment. As Kyle described, board
meetings include a “white-board” session which focuses organizational gaps in
skills what personal connections could help recruit volunteers to help meet these
needs. The FARA board is well established and financially healthy and well
connected as members include a congressman, a retired CEO of a highly visible
corporation and several other high-profile individuals. Their nomination
committee plays a key role in helping ensure they have access to those with the
skills necessary to meet the ever-changing needs of their constituents.
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Anne Catlin, Executive Director of Bournelyf Special Camp (BSC)
describes the evolution and maturation of BSC as largely dependent on a strong
board that started with a small group of parents and church members (the camp
is located on the grounds of a church) and has expanded to include others with
no affiliation with the church or camp. These other individuals include a lawyer,
CPA and an Executive Director of another local nonprofit organization. Bringing
in others from outside the camp community has had a tangible impact on
fundraising, addressing deferred maintenance needs of the camp and
implementing a solid and sustainable financial strategy. It has also enabled
Anne to focus more on developing her staff and implementing impactful
programs for the campers both during the camp season and during events held
each month, throughout the year.
Dr. Fajgenbaum from CDCN has supplemented his Board’s scientific
focus with volunteers from the University of Pennsylvania’s Wharton School of
Business. This has been a critical resource as CDCN has taken a business
execution approach towards administering a model that drives collaboration
amongst researchers and reaches broadly to gain access to the global scientific
community.
In the case of DCO and CRB1, both organizations have achieved a great
deal with limited resources. Much of this has been accomplished on the back of
a few active caregivers and in the case of DCO, patients. Leaders from both
organizations expressed that active board members were reaching “burn-out”
and as Kristin Smedley put it, they are reaching the “five-year drop-off”. As
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demonstrated in the DCO case study, the DCO Board realizes that to continue to
meet the needs of a growing patient database, it is critical that the Board
implement a strategic plan that engages others from within and outside the DCO
community. By dispersing governance they will have a greater ability to speed
up execution and accomplish more. This aligns with the research of Sarrow and
Jaskyte, which examine transformational leadership, and nonprofit management
and leadership effectiveness as presented in the literature review.
The strength of a strong board which could provide leadership in driving
and accelerating a rare disease organization’s capacity and influence to its
patients, partner organizations and other collaborators was presented in the DCO
case study as a “fly-wheel effect” where momentum comes from the center
leadership of the organization and is provided to those working towards its
mission. This was illustrated as follows:
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•

“Transformational Change” and “Adaptive Moves”
Two of the rare disease advocacy leaders interviewed acknowledged that

speed and urgency had a unique emphasized importance to those researching
and managing rare diseases, but they also recognized that a path to curing a
disease as Dr. Fajgenbaum described, is a “journey with many steps”. Dr.
Fajgenbaum also felt that “it is critical for rare disease organizations to think
beyond advocacy to scientific impact.”
Kyle Bryant felt it was important that not everything was measured to the
standard of a “cure” as there is so much to be done to improve and extend the
lives of rare disease patients. Each leader interviewed pointed to incremental
steps, moments or transformative goals towards advancing the quality of life for
their patients, families and caregivers. Generating awareness, whether by
means of publishing clinical guidelines as is the case with DCO and CDCN or
what Kyle Bryant refers to as “targeted awareness that brings a measurable
change” was cited as transformational. The rare disease organizations value the
work and results that are tangible, rather than simply creating exposure without
meaningful outcomes. Kristin Smedley spoke of a recent US House Resolution
recognizing “National Rare Eye Disease Day” that was written in braille as a
transformational moment as its press coverage brought about a great level of
dialogue to promote the capabilities of those impacted by blindness.
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Schein’s Humble Consulting model demonstrates an emphasis on
equipping the organization with the ability to generate a series of more modest
yet impactful adaptive moves rather than bold and obvious transformational
outcomes. Schein writes, “If the problem turns out to be complex… the client
and helper should engage in a dialogue to figure out a feasible adaptive move,
knowing that this may not solve the problem but will provide some comfort and
will reveal new information on the basis of which to figure out the next adaptive
move” (Schein, 2016, pp. 23-24). Schein’s words ring true as those interviewed
shared a perspective that there are many impactful and important steps towards
improving the quality of lives for those with rare diseases or other challenges that
often fall short of a “cure.”
•

Collaboration
Collaboration was another prevalent theme towards building capacity and

driving outcomes. Kristin Smedley, Robin Huiras and Lisa Helms-Guba spoke at
length about their organization’s alliances with NORD, the Genetic Alliance as
well as with other rare disease advocacy organizations. As many rare disease
patients may feel alone, organizations often feel lost while advocating for a
disease that has so few patients. Rare disease organizations, symposiums and
networking are all ways that leaders have described as ways of coming together
and sharing collective views and resources.
Another area of focus for collaboration is within the medical community.
This was discussed at length with Kyle Bryant and especially by Dr. Fajgenbaum,
who is a part of the medical and research community. Both Kyle and Dr.
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Fajgenbaum stressed how maintaining the visibility and presence of the rare
disease patient is a critical factor in driving researchers, who are often perceived
to be territorial and non-collaborative. In regard to Castleman Disease, Dr.
Fajgenbaum shares that “getting all doctors to share samples is especially
difficult. Good samples are hard to find; disaggregated research at research
institutions and hospital labs slow things down. Aggregating this knowledge
would definitely speed things up, unfortunately, not all researchers are interested
in doing this.” Dr. Fajgenbaum created a collaborative research model that has
been shared throughout the rare disease community. As both Dr. Fajgenbaum
and Kyle Bryant emphasize, keeping the patient at the center of research is what
will facilitate efficient and effective research outcomes. That feeling was also
shared by Robin Huiras as she described DCO’s success in recruiting and
maintaining an extremely knowledgeable and collaborative medical advisory
board, one of their most significant accomplishments as described by both Robin
and Lisa Helms-Guba.
•

Nonprofits working with consultants
Of the five organizations with leaders interviewed, three of them have

utilized outside consultants. FARA has used both a fundraising and two PR
consultants, Bournelyf has used a grant writer and strategic planning consultant
and DCO had recently engaged Bob Biglin and me as described in the case
study.
Kyle Bryant shared FARA’s experience with consultants as mixed. When
working with a fundraising consultant, they provided FARA with good ideas and
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direction that made a difference to their fund raising efforts. On the two
occasions of working with PR consultants, Kyle shared that neither went well as
in both cases the consultant did not understand the values or culture of FARA
nor did they understand why rare disease organizations are different. Kyle
appreciated the personalization process implemented by the fund raising
consultant. He also feels that consultants need to be visionary and tactical,
saying “you can’t have one, you need both.”
Anne Catlin’s experience with an outside consultant was positive as the
consultant had a history of working closely with the board and Executive Director
as a grant writer for a number of years before leading then through a strategic
planning process. Again, a high level of personalization had existed before
jumping into the engagement. Similar to Kyle, Anne felt that it was important that
the consultant be a bit prescriptive in terms of outlining a tactical plan after
leading the Board and camp families to a strategic vision. She also felt being a
good listener and working with data and filtering out emotions were valuable
attributes brought by a third party consultant. The skills, perspective, and
organization brought in by a consultant were all valuable elements that Anne
noted when describing her organization’s positive experience.
Many of the elements described by Kyle and Anne were also evident
during the DCO case study. Robin Huiras, DCO’s President at the time
described the engagement as “very helpful” and valued the collection of
synthesized outside information that was gathered and honest feedback that was
incorporated into goals and outcomes. Robin also noted that the Board was
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already aware of their problems and the Appreciative Inquiry approach used in
the engagement was “spot-on” feeling an Action Research approach would not
have been nearly as visionary or productive.
Conclusions
The stories and perspectives shared by Kyle Bryant, Kristin Smedley, Dr.
David Fajgenbaum, Anne Catlin, Robin Huiras and Lisa Helms-Guba
demonstrate that rare disease advocacy and small nonprofit organizations come
in many different sizes and have a varied set of resources and priorities. The
single most impactful value each of these organizations and their leaders share
is the importance of keeping the patient (or camper) first and in the forefront of
their mission and accomplishments. This is an important success factor as it has
been shown to drive collaboration and urgency, both critical elements in
facilitating research and outcomes for those struggling with diseases or
conditions that compromise their quality life and in many cases survival. Each
organization has also demonstrated and valued the benefit of a strong and
diverse board. In the case of FARA and CDCN, their Boards already include
active and passionate individuals with an abundance of access to others who can
help their organizations. In the case of DCO and CRB1, they are in the earlier
stages of building this capacity, but have a clear vision and plan in regard to how
to build upon their previous successes and engage others who can ensure the
growth and sustainability of their mission and organization. In the case of
Bournelyf, their Board and community engagement has facilitated significant
growth and financial stability over the past five years and they are now positioned
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to begin building endowments and address long-term challenges that will secure
the future of the camp for future generations.
Passion, drive, urgency, resilience, commitment, creativity and tenacity
are all attributes found in each of those interviewed. As rare disease patients
and caregivers face unique stressful challenges, it has been demonstrated that
employing a visionary and strength-based approach towards working with them
as a consultant or subject matter expert is an effective way of working towards
positive outcomes when faced with very life-and-death medical and wellness
issues.
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CHAPTER 5
CONCLUSIONS AND AREAS OF FURTHER DISCOVERY
Being a part of the rare disease community as a caregiver, bereaved
parent, advocate, consultant and now as an executive coach has been the most
tragic and rewarding part of my life over the past twenty-two years. As parents
and caregivers, my wife and I lived through an incredible life that our son gave to
our family, friends and community. We came to understand our own resilience
and frustration as we looked for an explanation for why our son was not growing
or thriving. When we found that answer with a diagnosis of a rare disorder, we
were determined to enable Josh to continue to live a happy and productive life
and avoided projecting what the future may hold for him as much as we could.
When Josh’s health began to deteriorate, we found ourselves working with more
urgency to connect with the few doctors and families that understood our
circumstance. We found a small and passionate community that was there to
help us and ensure we were exploring every option and receiving the best care
available for our son. After losing Josh to this devastating disease, I found
joining a Board that was working to advocate provided some healing and an
opportunity to tribute Josh, but eventually that became an impediment to coping
and living. At this time, I realized I could be much more effective in the DC and
rare disease community as a consultant and coach who could provide
perspective and counsel to help build and sustain a rare disease organization.
This capstone has provided a path to the next steps in this journey, one that has
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been inspired by my son and those that I’ve met at Penn and within the orphan
disease community.
The DCO case study examined my own personal journey and how a small
rare disease advocacy organization has been able to assemble an exceptional
medical advisory board and tirelessly work to support a growing number of
families who were often at the very beginning of a rare disease diagnosis and
journey. It also illustrated an organization that relied on very few people, each
either sick from the disease or relentlessly caring for a loved one that was
impacted with DC. Our consulting engagement with DCO exemplified a focus on
the positive and created a future vision to serve a community that is in great fear
and often despair in regard to the sorrow they encounter every day. We found
this approach to be effective as it enabled DCO’s leaders to develop a plan that
would require the help of others and build a board with the capacity to move
towards their vision of influencing more research and growing its resources to
support a growing number of patients and families.
The review of existing literature helped develop an understanding of what
separates rare disease advocacy organizations from other small nonprofit
organizations. Looking back at the history of the Rare Disease Act of 1983 and
how a few high-profile advocates were able to draw attention to this population
helped outline the unique challenges experienced when working towards bringing
attention to diseases that singularly are small in patient numbers, but collectively
represent one-in-ten individuals in the world’s population. The review examined
what makes the nonprofit sector special as compared to the for-profit enterprise
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sector. Examining the work of Peter Drucker and his influence upon Frances
Hesselbein as well as subsequent research into effective elements of leadership
and innovation in the nonprofit sector provided a template to further understand
successful ingredients of building capacity for nonprofit organizations. Lastly,
examining the consultant’s role in working with nonprofit organizations was
outlined in a review of the works of Penolope Cagney and Edgar Schein.
Schein’s philosophy of developing a helping relationship with a strong level of
personalization and partnering proved to be critical in providing effective
consultation to rare disease advocacy organizations as was demonstrated in the
DCO case study as well as in interviews with leaders of other nonprofit
organizations that were included in this capstone. This was further expanded
upon when examining the effectiveness of an Appreciative Inquiry approach as
compared to more traditional Action-Research techniques in consulting.
The final section of this capstone offered insights, opinions and incredible
stories from leaders of five small nonprofit organizations, four of them from the
rare disease community and the fifth from a camp that services many from this
same community. The importance of building organizational capacity and
acquiring people with relevant skill sets to help these “kitchen-table”
organizations are needed to supplement the efforts of a patient-centric board
resonated with each interview. The importance of collaboration within the
medical community and working to influence the science and research that was
being done was another theme that was shared amongst multiple people of
those interviewed. There is a common understanding that urgency and the need
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to move forward quickly are paramount and unique to rare disease organizations
as speed is truly a life-or-death issue. Most of all, each organization’s leader
shared the importance of having the patient and caregiver at the center of
everything that was done. There is a high level of self-advocacy within the rare
disease community and for others to help, whether as a consultant, paid
employee or volunteer, compassion and personalization of the patient’s struggle
is an essential ingredient to effectively help these organizations grow and thrive.
The capstone study explores a broad array of issues and complexities in
regard to nonprofit organizations and specifically those in the rare disease
community. Since Peter Drucker’s 1989 Harvard Business Review article, What
Businesses Can Learn From Nonprofits, there has been a great deal more
written and researched about the subject. Unfortunately, there has not been a
mass of research in regard to rare disease advocacy organizations. The DCO
case study serves as one example of work done with this community, but it is
only one example. Future focus on these organizations would be valuable in
helping leaders and practitioners in this community understand what processes
and techniques are most effective. In regard to examining what constitutes
transformational or innovative change within nonprofit organizations, further
definition of what truly is transformational or innovative and the cause and effect
of incremental steps in these cases would be relevant to the rare disease
community. As the DCO case took place less than a year ago, it is too soon to
access what changes were made and the results of these changes since the
consulting engagement ended. As I have remained involved with DCO and I am
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currently working as a coach to their new President, I do believe they will follow
through on a number of the recommended steps towards meeting the vision
they’ve outlined.
As someone who aspires to be a professional coach and consultant, and
as a member of the rare disease community, I feel very privileged to have
participated in this Capstone experience. The work and theories applied during
the DCO experience and the insights gained from other research and literature,
as well as the tremendous individuals I interviewed and learned from, have
positioned me to continue to grow and help others not only in the rare disease
community, but also in all sectors and professions. This has been a very
personal journey for me. Coaching and consulting is centered on relationships
and compassion. I look forward to continuing this journey as I give back to this
community as a coach and consultant.
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APPENDIX A
DCO ENGAGEMENT PROPOSAL

CONSULTING ENGAGEMENT BRIEFING
DOCUMENT: JULY 27, 2016

DYSKERATOSIS CONGENITA
OUTREACH, INC.
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USING APPRECIATIVE INQUIRY FOR SUSTAINABLE CHANGE

APPRECIATIVE INQUIRY (AI) IS A VISION-BASED APPROACH OF OPEN DIALOGUE THAT IS DESIGNED
TO HELP ORGANIZATIONS AND THEIR PARTNERS CREATE A SHARED VISION FOR THE FUTURE.
▸ It is highly participative, building stronger relationships in the
organization and with partners.
▸ It is future focused.
▸ It fosters optimism and hope.
▸ It draws on the resources, and resourcefulness of the organization.
▸ It focuses on the positive to crowd out the negative.
▸ It builds organizational capacity beyond existing boundaries.
Appreciative Inquiry is about the co-evolutionary search for the best in people, their
organizations, and the relevant world around them. In its broadest focus, it involves
systematic discovery of what gives “life” to a living system when it is most alive, most
effective, and most constructively capable in economic, ecological, and human
terms.
- David Cooperrider
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AI CHANGE STRATEGIES USE THE SOAR FRAMEWORK
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POSITIVE QUESTIONS AND DIALOGUE ARE AT THE HEART OF AI DRIVEN CHANGE

PROPOSED QUESTIONS FOR DCO CONVERSATIONS
▸ What are you most proud of that DCO has accomplished?
▸ What is your most positive memory of time working with DCO?
▸ When DCO is working at its best, how would you describe that?
What happens, who’s involved, what are the results?
▸ In your ideal world, what does DCO look like in five years?
▸ Can you describe DCO’s biggest strengths?
▸ What are the capabilities of the organization that you want to strengthen the
most?
▸ Who are partners that have the greatest impact on DCO’s success?
▸ What partnerships could be developed to enhance DCO success?
▸ When DCO is at its best, what are the core factors or strengths that give life to
DCO?
▸ What stakeholders have benefited the most from DCO?
▸ What stakeholders could DCO reach out to and expand their impact?
▸ What are the most valuable attributes contributed by DCO’s Board Members?
▸ What additional attributes or skills would you like others to bring to the Board?
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DCO CONSULTING ENGAGEMENT SCOPE & TIMELINE (1 OF 2)
▸
▸
▸
▸
▸
▸
▸

Wednesday, July 27th 9PM ET – Introduction Call with Board President, Treasurer and Secretary
Background and history of DC Outreach, Inc.
Identify Stakeholders, Resources and Needs
Outline timeline and objectives of engagement
Outline data gathering process and timeline
Design questions for those interviewed
Format and participation for interviews
Identify other data resources
Sunday, August 7th, 9PM ET – DCO Board Meeting

▸ Introduce engagement
▸ Monday, July 25 – Friday, September 2
▸ Interviews with Key Stakeholders & possible resources; include:
▸ Board Members
▸ DCO Families – include international (Pacific)
▸ Medical Advisors
▸ Pharma (Vin Milano)
▸ Penn’s Orphan Disease Center (Dr. Wilson, Samantha Charleston, Monique Molloy)
▸ Other
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DCO CONSULTING ENGAGEMENT SCOPE & TIMELINE (2 OF 2)

Sunday, September 4th – DCO Board Meeting
▸ Update Board
Saturday, September 17 – Sunday, September 18 – Camp
Sunshine

▸
▸
▸
▸

Share data with stakeholders
Develop and Design future state of DC Outreach
Build commitment and participation towards the future
Develop actionable objectives and establish ownership and
milestones

Sunday , October 2nd, 9PM ET – Board Meeting
▸ Share draft of strategic plan and agree on next steps
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APPENDIX B
CAMP SUNSHINE PRESENTATION
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APPENDIX C
DCO ACTION PLAN
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Key Activities

Send Call to Action email to DCO Community
Survey to DCO Community to prioritize most
critical activities to sustain, and frequency of
activities
Launch Fundraising campaign to raise funds for
part-time Executive Director
Review geographic concentrations of DCO
members and identify potential Chapter regions.
Develop Summary Description of Regional Chapter
and Chapter leads
Transition Board Presidency from Robin to Katie
Email DCO community, targeting members by
region, soliciting volunteers to start and lead
Regional Chapters.

Target Milestone

October 2016
October 2016
Nov 2016– Feb 2017
November 2016
December 2016
January 2017
January 2017

Prioritize
operations,
sustain
critical
functions

Establish
Regional
Chapters

Establish
Committees
Solicit
Volunteers

Fundraising &
Development

Hire Parttime
Executive
Director
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January 2017
Develop Job Description for Executive Director

Explore sources for Exec Dir candidates with
partner groups (NORD, Global Genes, etc.)

January 2017

February – May 2017
Exec Director candidate search and interviews
Hold kickoff conference call with Regional Chapter
leads

Key Activities

Hire and onboard part-time Executive Director
Develop scope of responsibilities and key skills for
each DCO Committee: Communication,
Development, Wellness & Advocacy, Medical,
Nominating
Enlist Regional Chapter Leaders to communicate
goals and needs of Committees to their respective
chapters, seeking volunteers and support.

March 2017

Target Milestone

May 2017
July 2016

August 2016

Prioritize
operations,
sustain
critical
functions

Establish
Regional
Chapters

Establish
Committees
Solicit
Volunteers

Fundraising &
Development

Hire Parttime
Executive
Director
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Establish Committee charters
Launch DCO functional committees

August 2016
September 2016
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APPENDIX D
AGGRETATION OF INTERVIEW DATA
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Data – The following is an aggregation of data from interviews conducted between February 1 – 15, 2017

Interview A
• Not one or two things
• Founding Board & President. Relationships
built one at a time.
• Relationships with neighbors, friends, coworkers,etc.
• Allow patient to have the choice to be
involved.

Interview 2
• Went from a disorder nobody heard of or
thought about to one of the first that
ophthalmologists now think about
• In 2016 local congressman submitted a
resolution on Rare Disease Day in braille – very
significant; Generated a lot of press; watershed moment.

Interview 3
• Initially the disease was thought about and
treated like cancer; Understood more with
other physicians that it is an immune disorder,
not a cancer. Reframed treatment & research.
• Recent development of a diagnostic model for
the disease, online now, soon to be published
in a leading hematology journal.
• Until recently, most clinical data came from
David. Discovered pathway that personalized
treatment.

What contributed
to these
successes?

• Creating a patient community
• Integrity – Each meeting starts with their core
values
• Mission, Vision, Strategic Plan used as a guide
• Bringing others to Board & organization with
relevant skill sets.
• What are gaps; who do they need; identify
personal connections – done on a white board

• Does not like the term “awareness” but does
believe in moving awareness into action
• Effective collaboration. Very visible in rare
disease community; speaks at symposiums
and is seen & heard.

What challenges
lie ahead for your
organization?

• Managing expectations
• Not judging everything in regards to if it’s a
“cure”; not healthy thinking. Recognize value
of incremental steps.
• Time is a barrier. Urgency a core value.
Speeding business deals & science process is
life-or-death.
• Funding/money is a problem that can be
figured out.

• Growing too fast, volunteer dropping (5-year
drop-off).
• Need professional help in certain areas.
• Open a Center of Excellence for patient care.

• Global community of researchers and
physicians connected; trust & know the global
community
• Huge involvement of patients. Patients
involved with the whole process
• Execution – developed a plan with many steps;
Not focused on “cure”, but many steps along
the way. Break down and execute like a
business plan.
• 2 mains sources of volunteer:
o Patient Communities
o Penn Community (Wharton & Med.
Students)
• Getting all doctors to share samples. Good
samples are hard to find; disaggregated
research at research institutions, hospital labs.
Need to gain access and coordinate and
accelerate research. Researchers are not
always interested in doing this.

What do you
consider the most
impactful
successes/greatest
accomplishments?
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Interview 1

Interview 2

What would you
consider
transformational
to your
organization?

• Targeted awareness; something measurable
that brings change.
• No such thing as a “general public”.

• House resolution in braille
• Difficult as blindness is not life-threatening,
but has large impact on quality of life
• Kristin strives to keep blindness in fore-front
o TED talk in March
o Writing a book
o Comcast commercial
• Resources & job losses are issues
• Likes to go to medical stds.to have them
involved in rare disease groups early; see
patient perspective

Has your
organization at any
time used a
consultant? If so,
what were the
most and least
effective aspects of
the consulting
engagement?

• Worked with fund raising consultant w/ good
results. Had good ideas and direction that
made a difference.
• Twice worked with 2 different PR consultants.
Neither went well.
o Did not understand values or culture
o Did not understand why rare disease groups
are different “because they’re rare”
• Effective consultants need to be visionary &
tactical. Can’t have just one, need both.

• Have not used a consultant
Collaboration is key – rare disease orgs
demonstrate this at high level
Work together to “Halt the train of sorrow”

Interview 3
• Bringing together patients and physicians
• Business plan – “International Research
Agenda”
• Publishing Diagnostic Criteria
• Biggest problem in rare disease orgs is
redundancy and fracturing; too many
foundations for the same disease; need to
collaborate and have less organizations for the
same disease. Critical to take action, speed
results.
• Think beyond advocacy to scientific impact;
push Drs. Don’t wait.
Has utilized Wharton students as consultants.
Volunteers are like consultants.
Rare diseases are often neglected, don’t get the
attention they need.
Family and patients with disease are more often
the people in the organization
Bigger sense of urgency – most meaningful work,
constants/volunteers are working directly with
patients
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Interview 4
• Financial stability – Now able to address
deferred maintenance, introduce new
programs and establish endowments
• Alumni trips – nice trips,
• Emergence of other leaders within camp staff
• Strategic plan now being implemented and
ready for a refresh

Interview 5
• DCO awarding a grant through Million Dollar
Bike Ride
• Clinical Guidelines – collaboration and
something that had not existed.

Interview 6
• Lisa started on the Board five years ago; she
sees the Board now as much more professional
and accountable.
• Focus on governance and compliance
(documentation, tax, insurance, etc.)
• Clinical Guidelines were a turning point
• Mail list has grown from 100 to 900
• Dr. Agarwal & Dr. Savage – developing the
Telomere consortium

What contributed
to these
successes?

• Alumni families – they see that they are
provided with quality trips and quality care.
Buy in from parents & staff
• Emphasis on quality, sees it now more as a
parent
• Moving from shoe-string budget to better
appearance of quality, safety
o Replacing vehicles/vans
o Updating obstacle course

• Clinical Guidelines – a lot of patience and
confidence. Very slow moving and Robin’s not
very patient.
• MDBR/Grant – Be able to ask for help. Being
“in need” is not a weakness, others are looking
for ways to help. Perseverance.
• Belief in self. Humble confidence. Ability to
convince others they are doing the right things
to help.

• Representing the patient is important. Doctors
are more willing to collaborate, as patients are
involved.
• Following a period of internal conflict, there
was an urgency to firm up the Board or it
would not survive.
• Important each member has a role

What challenges
lie ahead for your
organization?

•
•
•
•

• Sustainability – concerned about burn-out
• Non-board members need to help out more
o New board member from Camp Sunshine
will be a great asset

What would you
consider
transformational
to your
organization?

• Camp having its own space
• More frequency of events, particularly for
alumni
• Help alumni as adults; concerned about those
who age out

• Spreading awareness. Growing the group and
engaging more families.
• Group needs to find a way to get people
excited more than every 2 years (Camp).
Amplifying outcomes. Put things in the face of
members, show them it’s a cause worth
supporting
• Keep people engaged regardless of where they
are in the DC process
• Hiring a paid Executive Director to move our
mission forward.
• Funding and influencing a significant grant for
DC research

What do you
consider the most
impactful
successes/greatest
accomplishments?

Funding is always a challenge
Dependent on church grounds
Meeting needs of what parents want
Shifting population from Downs Syndrome to
broader spectrum of disabilities, mostly autism

• Involvement of more people, shared vision
• Not a lot of spare time, current board is maxed
–out
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Interview 4

Has your
organization at
any time used a
consultant? If so,
what were the
most and least
effective aspects
of the consulting
engagement?

Interview 5

• What makes NPO different:
o Needs more leading; brings in perspective
and skills

• Worked with Penn students to develop
strategic plan (subject of this capstone’s case
study)

o Camp is not everyone’s first job, secondary
• Strong understanding of NPO needs
• Good listener and patient – filter and not easily
swayed
• Organize thoughts and ideas
• Needs focus on succession planning;
prescriptive with some things

• Very helpful, synthesized outside information;
were able to get honest feedback and turn into
outcomes and goals.
• Concrete ideas; verbalized many things they
already know.
• AI approach was “spot on”
• Board was already aware of their problems;
would not have been productive to focus on
them.
• Group is young and leadership needed
inspiration.

Interview 6
• Medical Advisory Board – technical consultants
• NORAD is a great resource
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